WO2008092410A1 - Preparation method of thioureas or salts thereof - Google Patents

Preparation method of thioureas or salts thereof Download PDF

Info

Publication number
WO2008092410A1
WO2008092410A1 PCT/CN2008/070218 CN2008070218W WO2008092410A1 WO 2008092410 A1 WO2008092410 A1 WO 2008092410A1 CN 2008070218 W CN2008070218 W CN 2008070218W WO 2008092410 A1 WO2008092410 A1 WO 2008092410A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
formula
acid
alkyl
pit
Prior art date
Application number
PCT/CN2008/070218
Other languages
French (fr)
Chinese (zh)
Inventor
Jie Luo
Bo Lin
Wenrun Ye
Original Assignee
Chongqing Pharmaceutical Research Institute Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chongqing Pharmaceutical Research Institute Co., Ltd. filed Critical Chongqing Pharmaceutical Research Institute Co., Ltd.
Publication of WO2008092410A1 publication Critical patent/WO2008092410A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to a process for the preparation of a thiourea compound or a salt thereof. More specifically, the present invention relates to a process for producing a thiourea compound or a salt thereof by reacting an aminonitrile or a salt thereof with a thioamide in a suitable acidic medium. Background technique
  • a thiazole compound having antifungal activity (such as the compound represented by Formula 1-0) is a broad-spectrum antibacterial agent which has been produced in recent years;
  • Abafungin chemical name N-[4- [2- (2, 4-diphenylphenoxy)phenyl -2- thiazolyl] -1, 4, 5, 6 - tetrahydro-2-pyrimidinamine, as shown in formula (I), is the first thiazole ring antifungal with novel dual mechanism of action, killing both fungal cells in growth and in quiescence. It has the dual function of inhibiting fungi and killing fungi.
  • This drug is the first drug with this mechanism of action and is expected to be the first line of antifungal products.
  • the drug has a wide spectrum of antibacterial activity.
  • this product also has excellent inhibitory effect on yeast and Gram-positive bacteria. It has better effect on Candida than the current marketed varieties, so this product is expected to be used for treatment. ⁇ , vaginal candidiasis, vulvovaginitis (especially when bacteria are also involved), and certain bacterial dermatitis and acne.
  • the post-treated product is: under the hydrogen peroxide in an aqueous solution of (1, 4, 5, 6-tetrahydro-2-pyrimidin) nitrile (111) for 12 hours, then At 65 ⁇ 70 ° C, hydrogen sulfide is continuously passed for 25 ⁇ 30 hours, and the product is post-treated; "J. Med.
  • the present inventors have unexpectedly discovered that by using a conventional reaction apparatus, a suitable amino nitrile or a salt thereof can be reacted with a thioamide in a suitable acidic medium, and a thiourea compound can be smoothly produced in a short period of time. Its salt.
  • One aspect of the present invention provides a process for producing a thiourea compound represented by the formula ⁇ -0 or a salt thereof,
  • R, and R are each independently selected from hydrogen, d_ 2. Alkyl, d_ 2. Alkenyl, Ci.2o alkynyl, cycloalkyl radicals, cycloalkyl radicals -alkyl, C 6. 1 ( An aryl group, a 4-8 membered heterocyclic group having 1 to 3 hetero atoms, an aryl group, an alkyl group, an alkoxy group, an alkyl group, or a group represented by the following formula,
  • Ci_i. Pit base, 6_ ⁇ aryl base, pit ⁇ & pit base; R, R3 and R 4 are independently selected from hydrogen, fluorine, chlorine, bromine, iodine, d_ 2 . Alkyl, d_ 2 . Alkenyl, Ci.2o Block base, C-20 pit "? L3 ⁇ 4>, C3-10 ring pit base, C3-IO ring pit base Ci-io pit base, C6-10 aryl,
  • the method includes:
  • the compound of the formula (I 1-0) or its corresponding acid addition salt is obtained by reacting with a compound of the formula (I V-0) in a suitable acidic medium.
  • step (b) optionally, converting the compound of the formula ( ⁇ -0) obtained in the step (a) or an acid addition salt thereof to the desired salt or the formula (I 1-0) obtained in the step (a)
  • the acid addition salt of the indicated compound is deacidified to the free compound of the formula ( ⁇ -0).
  • R, and R" are, independently of each other, selected from the group consisting of hydrogen, alkyl, alkenyl, Cw.
  • Block C 3--8 cycloalkyl, C 3--8 cycloalkyl - 6 alkyl, C 6 - 8 aryl, 5-6 membered heterocyclyl containing 1-2 heteroatoms, C 6 - 8 aryl d- a 6 alkyl group, a d- 6 alkoxy d- 6 alkyl group, or a group represented by the following formula,
  • represents hydrogen, . Alkyl, . Alkenyl, Cw. Alkynyl group, C 3 - 7 cycloalkyl C 1-6 alkyl, C 6 - 8 aryl d- 6 alkyl, d- 6 alkoxy-d- 6 alkyl group; R 2, 1 3 and 14 to each other Independently selected from the group consisting of hydrogen, fluorine, chlorine, bromine, iodine, alkyl, alkenyl, and block. Alkoxy 3 ⁇ 4L, C3-7 ring C3-7 ring Cl-6 . 6-8 Fang &,. 6-8 aryl & Cl-6 Cl-6
  • R 5 represents. Alkyl, Cwo alkenyl, . Alkynyl, C 3 - 7 ring
  • one of R, and R" is hydrogen and the other is hydrogen, ( ⁇ - 6 alkyl, D- 6 alkenyl, d- 6 a group, a C 3 -6 cycloalkyl group, a C 3 - 6 cycloalkyl d- 6 alkyl group, a C 6 - 7 aryl group, or a group of the formula:
  • represents hydrogen, d- 6 alkyl
  • R 2 , R 3 and R 4 are independently selected from hydrogen, fluorine,
  • 15 represents an anthracenyl group, an ethyl group, a n-propyl group, an isopropyl group, an n-butyl group, an isobutyl group, a n-pentyl group, an isopentyl group, an n-hexyl group, an n-octyl group or 2 -ethylhexyl.
  • the compound represented by the formula ( ⁇ - 0 ) is a compound represented by the formula ( ⁇ ) or a salt thereof
  • the compound represented by the formula (II I- 0 ) is a compound of the formula (III) a compound or a salt thereof
  • the compound represented by the formula (IV-0) is a compound represented by the formula (IV).
  • the compound of the formula (111) or a salt thereof is reacted with a compound of the formula (IV) in a suitable acidic medium to give the corresponding addition salt of the compound of the formula (II).
  • the acid addition salt of the compound of formula (I I) can be further converted to the desired salt or deacidified to the free compound of formula (I I).
  • an acid addition salt of the compound of the formula (11-0) is formed in the step (a).
  • the formation of the addition salt advantageously improves the post-treatment process.
  • the acid addition salt of the compound of the formula ((-0) may be cooled, preferably cooled to - more preferably cooled to room temperature, and then filtered, optionally dried, preferably at room temperature or The acid addition salt is obtained by drying at a temperature between room temperature and the decomposition temperature of the acid addition salt of the compound of the formula (I I - 0 ).
  • a suitable "acid medium” which can be used in the step (a) may be a liquid acid itself, an acid solution or a solid acid system, etc., which can provide acidic conditions as well as reactants or products. Dispersed among them.
  • the acid moiety in the "acid medium” may be any protic acid (i.e., a donor of protons) that is suitable.
  • a liquid acid can be employed as the acidic medium.
  • “Liquid acid” means an acid which is liquid under the reaction conditions, such as phosphoric acid, polyphosphoric acid, citric acid, acetic acid, hydrazine sulfonic acid, trifluoroacetic acid, or a suitable mixture thereof.
  • an "acid solution” may be used as the acidic medium, and an “acid solution” means an acid solute such as hydrogen chloride, hydrogen bromide, hydrogen iodide, sulfuric acid, phosphoric acid, sodium hydrogen sulfate, potassium hydrogen sulfate.
  • the "acid medium” can be a solid acid system comprising a solid acid as the dispersed or stationary phase and a suitable solvent as the continuous or mobile phase.
  • a solid acid when referring to a solid acid, it refers to a solid acid, including sulfuric acid, phosphoric acid, boric acid or miscellaneous supported on a carrier of activated carbon, silica, alumina or diatomaceous earth.
  • a polyacid, or an acidic ion exchange resin such as an acidic ion exchange resin such as 001 x 2 type, 001 x 4 type, 001 x 7 type, or D113 type), which can be used as a dispersed phase or a stationary phase.
  • a suitable solvent is also included as a continuous phase or a mobile phase.
  • the solvent in the acid solution and the solid acid system is suitable for the acid solute and the solid acid used, and may be selected from the group consisting of hydrazine, hydrazine-dimercaptoamide, hydrazine, hydrazine-dimercaptoacetamide, hydrazine.
  • the selected solvent generally has a certain solubility to the acid solute and the reactant, and under the reaction conditions, Acid solutes do not produce chemical changes that affect the main reaction.
  • the acid solute is selected from the group consisting of hydrogen chloride, hydrogen bromide, hydrogen iodide, sulfuric acid, or phosphoric acid, or a mixture thereof, and the solvent may be selected from the group consisting of hydrazine, hydrazine-dimercaptoamide, hydrazine, hydrazine-dioxin.
  • the acid solute is selected from the group consisting of citric acid, acetic acid, sulfonic acid or phthalic acid, or a mixture thereof
  • the solvent may be selected from the group consisting of hydrazine, hydrazine-dihydrazinamide, hydrazine, hydrazine- Dimercaptoacetamide, fluorenyl-hydrazinopyrrolidone, water, ethylene glycol dioxime ether, tetrahydrofuran, trichlorodecane, disulfoxide, etc., or a suitable mixed solvent thereof.
  • the acid solute is selected from the group consisting of sodium hydrogen sulfate, potassium hydrogen sulfate, sodium hydrogen phthalate or potassium hydrogen phthalate, or a compound thereof
  • the solvent may be selected from the group consisting of ruthenium, osmium-two. Mercaptoamide, hydrazine, hydrazine-dimercaptoacetamide, fluorenyl-hydrazinopyrrolidone, water, disulfoxide, etc., or a suitable mixed solvent thereof.
  • the acidic medium is selected from the group consisting of hydrazine of hydrogen chloride, hydrazine-dihydrazinamide solution, hydrazine of hydrogen chloride, hydrazine-dimercaptoacetamide solution, sterol solution of hydrogen chloride, hydrogen chloride Ethanol solution, n-propanol solution of hydrogen chloride, hydrochloric acid, ethyl acetate solution of hydrogen chloride, tetrahydrofuran solution of hydrogen chloride, hydrobromic acid, hydroiodic acid, phosphoric acid and phosphoric acid aqueous solution, sulfuric acid aqueous solution, decyl sulfate solution, sulfuric acid ethanol solution, Polyphosphoric acid, citric acid, acetic acid, trifluoroacetic acid, aqueous acetic acid and tetrahydrofuran acetate solution, preferably a solution of hydrogen chloride, a solution of hydrazin
  • a “liquid acid” or “acid solution” is used in the present invention as an acidic medium, the amount thereof can be conventionally determined by those skilled in the art. For example, it may be used in an amount of from 2 to 40 times, preferably from 5 to 20 times the weight of the compound of the formula (III-0) or a salt thereof.
  • the acid solutes in the “acid solution” are generally in excess relative to the compound of the formula (IV-0), up to the amount of saturation of the acid in the solvent.
  • the "salts" of the compounds of formula (?-0) in step (a) include, but are not limited to, hydrochloride, sulfate or hydrobromide, and the like.
  • the compound of the formula (IV-0) is used in an amount of from 1 to 10 mol, preferably from 1 to 3 mol, per mol of the compound of the formula (III-0) or a salt thereof.
  • the reaction temperature in the step (a) is generally to the boiling point of the medium.
  • the reaction temperature may preferably be from room temperature to the boiling point of the solution.
  • the lower limit of the reaction temperature may be preferably room temperature, and the upper limit is preferably lower than the reflux temperature.
  • the reaction pressure is preferably atmospheric pressure, but when the required reaction temperature exceeds the atmospheric boiling point of the medium, the boiling point of the medium can be increased to or above the desired reaction temperature by pressurization. The boiling point of the medium at different pressures is common knowledge in the art.
  • the obtained product is generally an acid addition salt formed by the compound represented by the formula ( ⁇ -0) and the acid in the medium, and if subjected to a post-treatment operation such as filtration or concentration, The acid addition salt of the compound of the formula (?-0) can be directly obtained; if the post-treatment is carried out by neutralization and re-separation, a compound of the formula (?-0) can be obtained.
  • step (b) is an optional step, and the presence thereof may be determined as needed. If desired, the acid addition salt of the compound of the formula (I 1-0) obtained in the step (a) is exchanged to the desired salt, or the compound of the formula ( ⁇ -0) is formed into a desired compound.
  • salt such as hydrochloride, sulfate, hydrobromide, phosphate, sulfonium sulfonate, etc.
  • salt exchange techniques or salt formation techniques in the art; if it is to be obtained in step (a)
  • acid addition salt of the compound of the formula (?-0) is deacidified to a free compound of the formula (?-0), it can also be carried out according to a conventional deacidification technique in the art.
  • the reaction time is generally 0.5 to 6 hours, which is much longer than the prior art.
  • the reaction time is generally 0.5 to 6 hours, which is much longer than the prior art. shorten.
  • the post-treatment of the method of the invention is simple and convenient, generally can be directly filtered to obtain a product; the obtained product has good quality (HPLC purity is generally greater than 95%), and the yield is high (generally 60-90%), generally no complicated purification operation is required. Can be used directly under One step reaction.
  • the method further comprises reacting the obtained compound of the formula ( ⁇ -0) or a salt thereof with a compound represented by the formula (V-0),
  • R 6 represents a substituent represented by the following formula
  • R 7 , R 8 , ⁇ and ⁇ Respectively represent hydrogen, fluorine, chlorine, bromine, iodine, nitro,
  • Cl-4 pit foundation Cl-4 pit ⁇ L3 ⁇ 4 ⁇ , Cl-4 pit base, - (CH pit base) ⁇ , Cl-4 pit base, d- 4 alkylsulfinyl, d- 4 alkane arylsulfonyl group, or an 1-9 substituents selected from fluoro, chloro, bromo, iodo halogen atom halo 4 - alkyl, halo-D- 4 alkoxy group, halo --4 alkylthio, halo ( ⁇ -4 alkylsulfinyl or halo d- 4 alkylsulfonyl; Y represents oxygen, sulfur, sulfinyl or acyl; Ar represents unsubstituted or substituted by one, two or more substituents Phenyl, oc-naphthyl, P-naphthyl, tetrahydronaphthyl or anthracenyl, wherein
  • d- 4 alkylsulfonyl group a cycloalkyl group having 3-7 carbon atoms, or a phenyl d- 4 alkyl group, a phenoxy group or a phenoxy group d- 4 ,
  • R, and R are each independently selected from hydrogen, d_ 2.
  • Ci_io pit represents hydrogen, Cwo alkyl, Cwoalkenyl, Cwo alkynyl, C 3 .10 cycloalkyl Ci_io pit, 6-10 aryl Ci_io pit, Ci_io pit ⁇ & Ci_io pit; R, R3 and
  • R 4 is independently selected from the group consisting of hydrogen, fluorine, chlorine, bromine, iodine, and d_ 2 .
  • the practice of the reaction and the preparation of the compound of formula (V-0) can be carried out in accordance with the process disclosed in U.S. Patent 4,956,370.
  • R 6 represents a substituent represented by the following formula
  • R 7 , R 8 , ! ⁇ and ⁇ Each independently represents hydrogen, fluorine, chlorine, bromine, iodine, nitro, decyl, ethyl, decyloxy, ethoxy, decyloxy, ethoxy ⁇ , bismuth, and diethyl Or thiol, ethylthio, decylsulfinyl, ethanesulfinyl, decylsulfonyl, ethylsulfonyl, or having from 1 to 5 selected from fluorine, chlorine, bromine, Halogenated fluorenyl, haloethyl, halodecyloxy, haloethoxy, halothiol, haloethylthio, halodecylsulfinyl having the same or different halogen atoms of iodine , haloethylsulfin
  • the compound of the formula (I 1-0) or a salt thereof is a compound of the formula (II) or a salt thereof
  • the compound of the formula (V-0) is a formula (V) Or a compound represented by the formula (VI)
  • the compound of the formula (1-0) or a salt thereof is a compound of the formula (I) or a salt thereof.
  • Suitable times for the reaction in all of the above methods can be determined by one of ordinary skill in the art in accordance with conventional methods known, for example, by monitoring the progress of the reaction by conventional chromatography and spectroscopy techniques such as TLC and HPLC.
  • the present invention provides a method for preparing a thiourea compound represented by the formula (?-0), which eliminates the highly toxic malodorous hydrogen sulfide in the prior art, and greatly shortens the reaction time and improves the production efficiency. , simplifies the post-processing process.
  • the method is simple and convenient to operate, and all operations can be completed in conventional reaction equipment, and the obtained product has good quality and high yield, which is favorable for industrial production.
  • the present invention further applies the method to the preparation of a 2-thiazole compound (as shown in Formula 1-0), particularly abifene (1).
  • a 2-thiazole compound as shown in Formula 1-0
  • Og (1) 5mol) and about 10% (g/g) of hydrogen chloride / hydrazine, 1000 ml of hydrazine-dihydrazinamide solution, reacted at 80 ⁇ to the starting material (1, 4, 5, 6-tetrahydro- 2-pyrimidine) Disappeared (TLC monitors the progress of the reaction, developing solvent: ethyl acetate: decyl alcohol 10:1), which takes about 2 hours. After the reaction mixture was cooled, the title compound was obtained. HPLC: 98.66%;
  • IR (KBr): 3215, 3038, 2961, 2859, 1637, 1565, 1492, 1478, 1459, 1449, 1437, 1376, 1348, 1319, 1277, 1250, 1219, 1146, 1122, 1061, 858, 818, 763 , 745, 728, 707, 649 cm- 1 ;
  • the method of the invention eliminates the highly toxic malodorous hydrogen sulfide in the prior art, and greatly shortens the reaction time, improves the production efficiency, and simplifies the reaction and the post-treatment process.
  • the method is simple and convenient to operate, and can be completed in a conventional reaction equipment, and the obtained product has good quality and high yield, which is favorable for industrial production.

Abstract

The invention provides preparation method of thioureas or salts thereof. In particular, the invention provides method of preparing thioureas by reacting cyanamides or salts thereof with thioamides in proper acidic medium. The product can be used to prepare 2-aminothiazoles, such as antimycotic abafungin.

Description

制备硫脲化合物或其盐的方法 技术领域  Method for preparing thiourea compound or salt thereof
本发明涉及硫脲化合物或其盐的制备方法。更具体而言,本发明 涉及利用氨基腈或其盐在适宜的酸性介质中与硫代酰胺反应制备硫 脲化合物或其盐的方法。 背景技术  The present invention relates to a process for the preparation of a thiourea compound or a salt thereof. More specifically, the present invention relates to a process for producing a thiourea compound or a salt thereof by reacting an aminonitrile or a salt thereof with a thioamide in a suitable acidic medium. Background technique
具有抗真菌活性的 噻唑类化合物(如式 1-0所示的化合物 ) 是近年发;^来的广谱抗菌药,
Figure imgf000002_0001
A thiazole compound having antifungal activity (such as the compound represented by Formula 1-0) is a broad-spectrum antibacterial agent which has been produced in recent years;
Figure imgf000002_0001
其中的阿巴芬净(Abafungin ), 化学名为 N- [4- [2- (2, 4-二曱基 苯氧基)苯基〗 -2-噻唑基〗 -1, 4, 5, 6-四氢- 2-嘧啶胺, 结构如式( I ) 所示, 是第一个噻唑环类抗真菌药,具有新颖的双重作用机制, 对生 长中和静止中的真菌细胞均具有杀灭作用,具有抑制真菌和杀灭真菌 的双重作用,该药是具有这种作用机制的第一个药物,有望成为抗真 菌的一线产品。该药抗菌谱广, 除抗真菌效果卓越外, 本品对酵母菌 和革兰氏阳性菌也有优良的抑制作用,对念珠菌的作用优于目前上市 品种, 因此本品还有望能用于治疗曱癣、 阴道念珠菌病、外阴阴道炎 (特别是在细菌也卷入时)、 以及某些细菌性皮肤炎和痤疮等。  Among them, Abafungin, chemical name N-[4- [2- (2, 4-diphenylphenoxy)phenyl -2- thiazolyl] -1, 4, 5, 6 - tetrahydro-2-pyrimidinamine, as shown in formula (I), is the first thiazole ring antifungal with novel dual mechanism of action, killing both fungal cells in growth and in quiescence. It has the dual function of inhibiting fungi and killing fungi. This drug is the first drug with this mechanism of action and is expected to be the first line of antifungal products. The drug has a wide spectrum of antibacterial activity. In addition to excellent antifungal effect, this product also has excellent inhibitory effect on yeast and Gram-positive bacteria. It has better effect on Candida than the current marketed varieties, so this product is expected to be used for treatment.曱癣, vaginal candidiasis, vulvovaginitis (especially when bacteria are also involved), and certain bacterial dermatitis and acne.
Figure imgf000002_0002
Figure imgf000002_0002
( I ) ( ID ( III ) 硫脲化合物是制备此类抗真菌活性的 2-氨基噻唑类化合物的关 键中间体。 例如(1, 4, 5, 6-四氢- 2-嘧啶基)硫脲(结构如式 II 所示) 是制备阿巴芬净的关键中间体。 目前文献公开的(1, 4, 5, 6-四氢- 2- 嘧啶基)硫脲(Π)的制备方法是将(1, 4, 5, 6-四氢- 2-嘧啶基)氨基腈 (结构如式 III所示,可按 "J. Org. Chem., 1973, 38 (1): 155 ~ 156. " 中公开的制备方法制得。)与硫化氢(H2S)反应。如, "Arzneim- Forsh, 1985, 35 (3) : 573 - 577. " 中公开的(1, 4, 5, 6-四氢- 2-嘧啶基)硫脲 (II)的制备方法为:硫化氢饱和的曱醇溶液中加入(1, 4, 5, 6-四氢- 2- 嘧啶基)氨基腈(ΙΠ)和硫氢化钾(KHS),在高压釜中 70 ~ 80 下反应 16小时,经后处理得产品; US4581453中公开的制备方法为: 下, 在(1, 4, 5, 6-四氢-2-嘧¾^) ^腈(111)的水溶液中通硫化氢 12小 时, 然后在 65 ~ 70°C下, 再继续通硫化氢 25 ~ 30小时, 经后处理得 产品; "J. Med. Chem. , 1990, 33 (2): 534 - 552. " 中公开的制备方 法为: 在 下, 向(1, 4, 5, 6-四氢-2-嘧¾^) ^腈(111)和二乙胺 的曱醇溶液中通硫化氢 45分钟, 然后在钢弹中在 下加热 20小 时, 经后处理得产品。 可见, 以上技术都存在反应时间较长、 工业化 时对设备及保障措施要求较高等不足之处。 发明内容 (I) (ID (III) Thiourea compounds are key intermediates in the preparation of such antifungal 2-aminothiazoles. For example (1, 4, 5, 6-tetrahydro-2-pyrimidinyl) thiourea (Structural as shown in Formula II) is a key intermediate for the preparation of abifene. The preparation method of (1, 4, 5, 6-tetrahydro-2-pyrimidinyl) thiourea (Π) disclosed in the literature is (1, 4, 5, 6-tetrahydro-2-pyrimidinyl) aminonitrile (structure shown in Formula III, can be referred to as "J. Org. Chem., 1973, 38 (1): 155 ~ 156." The preparation method disclosed in the preparation is obtained. ) reacts with hydrogen sulfide (H 2 S). For example, "Arzneim-Forsh, 1985, 35 (3): 573 - 577." The preparation method of (1, 4, 5, 6-tetrahydro-2-pyrimidinyl) thiourea (II) is as follows: vulcanization (1, 4, 5, 6-tetrahydro-2-pyrimidinyl) aminonitrile (ΙΠ) and potassium hydrogen hydride (KHS) were added to a hydrogen-saturated decyl alcohol solution, and reacted in an autoclave at 70 to 80 for 16 hours. The post-treated product; the preparation method disclosed in US 4,451,453 is: under the hydrogen peroxide in an aqueous solution of (1, 4, 5, 6-tetrahydro-2-pyrimidin) nitrile (111) for 12 hours, then At 65 ~ 70 ° C, hydrogen sulfide is continuously passed for 25 ~ 30 hours, and the product is post-treated; "J. Med. Chem., 1990, 33 (2): 534 - 552." : Underneath, hydrogen sulfide is passed to a solution of (1, 4, 5, 6-tetrahydro-2-pyrimidine) and nitrile (111) and diethylamine in decyl alcohol for 45 minutes, then heated in a steel bomb under 20 Hours, after treatment, the product. It can be seen that the above technologies all have shortcomings such as long reaction time and high requirements for equipment and safeguard measures during industrialization. Summary of the invention
本发明人出乎意料地发现利用常规反应设备,在适宜的酸性介质 中, 将合适的胺基腈或其盐与硫代酰胺反应, 在较短时间内, 可以顺 利的制得硫脲化合物或其盐。  The present inventors have unexpectedly discovered that by using a conventional reaction apparatus, a suitable amino nitrile or a salt thereof can be reacted with a thioamide in a suitable acidic medium, and a thiourea compound can be smoothly produced in a short period of time. Its salt.
本发明一方面提供一种制备式 Π- 0所示硫脲化合物或其盐的方 法,  One aspect of the present invention provides a process for producing a thiourea compound represented by the formula Π-0 or a salt thereof,
Figure imgf000003_0001
其中, R,和 R"相互独立地选自氢、 d_2。烷基、 d_2。烯基、 Ci.2o 炔基、 。环烷基、 。环烷基 。烷基、 C6.1()芳基、 含有 1-3个 杂原子的 4-8元杂环基、 。芳基 。烷基、 。烷氧基 。烷基、 或下式所示基团,
Figure imgf000003_0001
Wherein, R, and R "are each independently selected from hydrogen, d_ 2. Alkyl, d_ 2. Alkenyl, Ci.2o alkynyl, cycloalkyl radicals, cycloalkyl radicals -alkyl, C 6. 1 ( An aryl group, a 4-8 membered heterocyclic group having 1 to 3 hetero atoms, an aryl group, an alkyl group, an alkoxy group, an alkyl group, or a group represented by the following formula,
Figure imgf000003_0002
Figure imgf000003_0002
其中 代表氢、 Cwo烷基、 Cwo烯基、 Cwo炔基、 C3.10环烷基Which represents hydrogen, Cwo alkyl, Cwoalkenyl, Cwo alkynyl, C 3 .10 cycloalkyl
Ci_i。坑基、 6_ιο芳基 坑基、 坑^ & 坑基; R、 R3和 R4相互独立地选自氢、 氟、 氯、 溴、碘、 d_2。烷基、 d_2。烯基、 Ci.2o 块基、 C -20坑"? L¾>、 C3-10环坑基、 C3-IO环坑基 Ci-io坑基、 C6-10芳基、Ci_i. Pit base, 6_ιο aryl base, pit ^ & pit base; R, R3 and R 4 are independently selected from hydrogen, fluorine, chlorine, bromine, iodine, d_ 2 . Alkyl, d_ 2 . Alkenyl, Ci.2o Block base, C-20 pit "? L3⁄4>, C3-10 ring pit base, C3-IO ring pit base Ci-io pit base, C6-10 aryl,
C6-io芳基 CJ.JO坑基、 CJ.JO坑 ·?^¾· CJ.JO坑基, C6-io aryl CJ.JO pit base, CJ.JO pit ·?^3⁄4· CJ.JO pit base,
该方法包括:  The method includes:
(a)、 将式(III- 0)所示化合物或其盐  (a), a compound of the formula (III-0) or a salt thereof
R'- -N- EN  R'- -N- EN
R" ( III— 0) R" ( III - 0)
其中, R,和 R"的定义同上,  Where R, and R" are as defined above,
在适宜的酸性介质中与式(I V-0)所示化合物反应,制得式 (I 1-0) 所示化合物或其相应的酸加成盐,  The compound of the formula (I 1-0) or its corresponding acid addition salt is obtained by reacting with a compound of the formula (I V-0) in a suitable acidic medium.
申, R5 Cl-10 ¾ &、 。6-ιο芳&
Figure imgf000004_0001
Shen, R5 Cl-10 3⁄4 &, . 6-ιο芳&
Figure imgf000004_0001
(b)、任选地,将步骤(a)得到的式(Π- 0)所示化合物或其酸加成 盐转化成所需的盐或将步骤(a)得到的式(I 1-0)所示化合物的酸加成 盐脱酸成游离的式(Π- 0)所示化合物。  (b) optionally, converting the compound of the formula (Π-0) obtained in the step (a) or an acid addition salt thereof to the desired salt or the formula (I 1-0) obtained in the step (a) The acid addition salt of the indicated compound is deacidified to the free compound of the formula (Π-0).
根据本发明的某些实施方案, 其中在式(Π- 0)和式(III-0) 中, R,和 R"相互独立地选自氢、 烷基、 烯基、 Cw。块基、 C3-8 环烷基、 C38环烷基 -6烷基、 C68芳基、 含有 1-2个杂原子的 5-6元 杂环基、 C6-8芳基 d-6烷基、 d-6烷氧基 d-6烷基、 或下式所示基团, According to some embodiments of the invention, wherein, in the formula (Π-0) and formula (III-0), R, and R" are, independently of each other, selected from the group consisting of hydrogen, alkyl, alkenyl, Cw. Block, C 3--8 cycloalkyl, C 3--8 cycloalkyl - 6 alkyl, C 6 - 8 aryl, 5-6 membered heterocyclyl containing 1-2 heteroatoms, C 6 - 8 aryl d- a 6 alkyl group, a d- 6 alkoxy d- 6 alkyl group, or a group represented by the following formula,
Figure imgf000004_0002
Figure imgf000004_0002
其中, ^代表氢、 。烷基、 。烯基、 Cw。炔基、 C3-7环烷基 C 1-6 烷基、 C68芳基 d-6烷基、 d-6烷氧基 d-6烷基; R2、 13和14相互独立地 选自氢、 氟、 氯、 溴、 碘、 烷基、 烯基、 块基、 。烷氧¾L、 C3— 7环 C3-7环 Cl-6
Figure imgf000004_0003
。6— 8芳&、 。6一8芳& Cl-6 Cl-6
Figure imgf000004_0004
Where ^ represents hydrogen, . Alkyl, . Alkenyl, Cw. Alkynyl group, C 3 - 7 cycloalkyl C 1-6 alkyl, C 6 - 8 aryl d- 6 alkyl, d- 6 alkoxy-d- 6 alkyl group; R 2, 1 3 and 14 to each other Independently selected from the group consisting of hydrogen, fluorine, chlorine, bromine, iodine, alkyl, alkenyl, and block. Alkoxy 3⁄4L, C3-7 ring C3-7 ring Cl-6
Figure imgf000004_0003
. 6-8 Fang &,. 6-8 aryl & Cl-6 Cl-6
Figure imgf000004_0004
在式(IV- 0) 中, R5代表 。烷基、 Cwo烯基、 。炔基、 C3-7In the formula (IV-0), R 5 represents. Alkyl, Cwo alkenyl, . Alkynyl, C 3 - 7 ring
Cl-6 Ce-8芳& Cl-6 Cl-6
Figure imgf000004_0005
Cl-6 Ce-8 Fang & Cl-6 Cl-6
Figure imgf000004_0005
根据本发明的某些优选实施方案,其中在式( Π-0)和式( III-0) 中, R,和 R"中的一个为氢, 另一个为氢、 (^-6烷基、 d—6烯基、 d—6块 基、 C3-6环烷基、 C3-6环烷基 d-6烷基、 C6-7芳基、 或下式所示基团, According to some preferred embodiments of the invention, wherein in the formula ( Π-0) and formula (III-0), one of R, and R" is hydrogen and the other is hydrogen, (^- 6 alkyl, D- 6 alkenyl, d- 6 a group, a C 3 -6 cycloalkyl group, a C 3 - 6 cycloalkyl d- 6 alkyl group, a C 6 - 7 aryl group, or a group of the formula:
Figure imgf000005_0001
Figure imgf000005_0001
其中, ^代表氢、 d-6烷基; R2、 R3和 R4相互独立地选自氢、 氟、Wherein ^ represents hydrogen, d- 6 alkyl; R 2 , R 3 and R 4 are independently selected from hydrogen, fluorine,
¾i、 Cl Cl 3⁄4i, Cl Cl
在式(IV- 0 )中, 1 5代表曱基、 乙基、 正丙基、异丙基、 正丁基、 异丁基、 正戊基、 异戊基、 正己基、 正辛基或 2-乙基己基。 In the formula (IV-0), 15 represents an anthracenyl group, an ethyl group, a n-propyl group, an isopropyl group, an n-butyl group, an isobutyl group, a n-pentyl group, an isopentyl group, an n-hexyl group, an n-octyl group or 2 -ethylhexyl.
在本发明更具体的实施方案中,式( Π- 0 )所示的化合物是式(Π) 所示的化合物或其盐, 式( I I I- 0 )所示的化合物是式(I I I)所示的化 合物或其盐, 并且式(IV- 0 )所示的化合物是式(IV)所示的化合物,  In a more specific embodiment of the present invention, the compound represented by the formula ( Π - 0 ) is a compound represented by the formula (Π) or a salt thereof, and the compound represented by the formula (II I- 0 ) is a compound of the formula (III) a compound or a salt thereof, and the compound represented by the formula (IV-0) is a compound represented by the formula (IV).
Figure imgf000005_0002
Figure imgf000005_0002
其中,式( 111 )所示化合物或其盐在适宜的酸性介质中与式( I V ) 所示化合物反应得到式(I I )所示化合物的相应的加成盐。 任选地, 该式(I I)所示化合物的酸加成盐可进一步转化成所需的盐或脱酸成 游离的式(I I)所示化合物。  Wherein the compound of the formula (111) or a salt thereof is reacted with a compound of the formula (IV) in a suitable acidic medium to give the corresponding addition salt of the compound of the formula (II). Optionally, the acid addition salt of the compound of formula (I I) can be further converted to the desired salt or deacidified to the free compound of formula (I I).
可选地,在本发明的上述方法中,在步骤(a )中形成的是式(11-0 ) 所示化合物的酸加成盐。加成盐的形成有利地改善了后处理过程。例 如, 所述式( Π-0 )所示化合物的酸加成盐可经冷却, 优选地冷却至 - 至 更优选地冷却至室温而析出,然后过滤,任选地干燥, 优选地在室温或高于室温至式( I I- 0 )所示化合物的酸加成盐的分解 温度之间的温度下干燥, 从而得到该酸加成盐。  Alternatively, in the above process of the present invention, an acid addition salt of the compound of the formula (11-0) is formed in the step (a). The formation of the addition salt advantageously improves the post-treatment process. For example, the acid addition salt of the compound of the formula ((-0) may be cooled, preferably cooled to - more preferably cooled to room temperature, and then filtered, optionally dried, preferably at room temperature or The acid addition salt is obtained by drying at a temperature between room temperature and the decomposition temperature of the acid addition salt of the compound of the formula (I I - 0 ).
在本发明方法的中, 步骤(a)中可应用的适宜 "酸性介质" 可以 是指液态酸本身、酸溶液或者固体酸系统等,其既可以提供酸性条件, 又可以使反应物或生成物在其中分散。 "酸性介质" 中酸部分可以是 适宜的任何质子酸(即质子的给予体)。  In the process of the present invention, a suitable "acid medium" which can be used in the step (a) may be a liquid acid itself, an acid solution or a solid acid system, etc., which can provide acidic conditions as well as reactants or products. Dispersed among them. The acid moiety in the "acid medium" may be any protic acid (i.e., a donor of protons) that is suitable.
在本发明的一些具体实施方案中, 可以采用液态酸作为酸性介 质。 "液态酸"是指在反应条件下呈液态的酸, 例如磷酸、 多聚磷酸、 曱酸、 乙酸、 曱磺酸、 三氟乙酸, 或它们适宜的混合物。 在本发明的 又一些具体实施方案中, 可以采用 "酸溶液" 作为酸性介质, "酸溶 液"是指其中含有酸溶质, 例如氯化氢、 溴化氢、 碘化氢、 硫酸、 磷 酸、 硫酸氢钠、 硫酸氢钾、 曱酸、 乙酸、 曱磺酸、 邻苯二曱酸、 邻苯 二曱酸氢钠、 邻苯二曱酸氢钟, 或其适宜混合物的溶液。 In some embodiments of the invention, a liquid acid can be employed as the acidic medium. "Liquid acid" means an acid which is liquid under the reaction conditions, such as phosphoric acid, polyphosphoric acid, citric acid, acetic acid, hydrazine sulfonic acid, trifluoroacetic acid, or a suitable mixture thereof. In the invention In still other embodiments, an "acid solution" may be used as the acidic medium, and an "acid solution" means an acid solute such as hydrogen chloride, hydrogen bromide, hydrogen iodide, sulfuric acid, phosphoric acid, sodium hydrogen sulfate, potassium hydrogen sulfate. A solution of citric acid, acetic acid, sulfonic acid, phthalic acid, sodium hydrogen phthalate, hydrogen phthalate, or a suitable mixture thereof.
在一些实施方案中, "酸性介质" 可以是固体酸系统, 其包括作 为分散相或固定相的固体酸和作为连续相或流动相的适宜溶剂。在本 发明中, 当提及固体酸时, 指的^ ^应 ^下呈固态的酸, 包括固载 在活性碳、 氧化硅、 氧化铝或硅藻土载体上的硫酸、磷酸、硼酸或杂 多酸、 或酸性离子交换树脂(如 001 x 2型、 001 x 4型、 001 x 7型、 D113型等酸性离子交换树脂), 其可作为分散相或固定相。 在固体酸 系统中,还包含作为连续相或流动相的适宜溶剂。酸溶液和固体酸系 统中的溶剂是与所用酸溶质和固体酸相适宜的, 其可选自下列的物 质: Ν, Ν-二曱基曱酰胺、 Ν, Ν-二曱基乙酰胺、 Ν-曱基吡咯烷酮、曱醇、 乙醇、 正丙醇、 异丙醇、 水、 乙二醇二曱醚、 四氢呋喃、 异丙醚、 乙 酸乙酯、 丙酮、 环己酮、 三氯曱烷、 四氯曱烷、 二曱亚砜、 曱酸、 乙 酸,或它们的混合物。本领域技术人员可以根据现有技术中已有技术 常规地选择 "与所用酸溶质相适宜的溶剂", 例如所选的溶剂一般应 对酸溶质及反应物有一定的溶解度,而且在反应条件下与酸溶质不产 生影响主反应的化学变化。在一些实施方案中,所述酸溶质选自氯化 氢、 溴化氢、碘化氢、硫酸或磷酸, 或其混合物, 溶剂可以选自 Ν, Ν- 二曱基曱酰胺、 Ν, Ν-二曱基乙酰胺、 Ν-曱基吡咯烷酮、 曱醇、 乙醇、 正丙醇、异丙醇、水、 乙二醇二曱醚、 四氢呋喃、 乙酸乙酯、异丙醚、 曱酸、 乙酸等, 或它们适宜的混合溶剂。 在另一些实施方案中, 所述 酸溶质选自曱酸、 乙酸、 曱磺酸或邻苯二曱酸、 或其混合物, 溶剂可 以选自 Ν, Ν-二曱基曱酰胺、 Ν, Ν-二曱基乙酰胺、 Ν-曱基吡咯烷酮、 水、 乙二醇二曱醚、 四氢呋喃、 三氯曱烷、 二曱亚砜等, 或它们适宜 的混合溶剂。在另一些实施方案中, 所述酸溶质选自硫酸氢钠、硫酸 氢钾、邻苯二曱酸氢钠或邻苯二曱酸氢钾、或其化合物, 溶剂可以选 自 Ν, Ν-二曱基曱酰胺、 Ν, Ν-二曱基乙酰胺、 Ν-曱基吡咯烷酮、 水、 二曱亚砜等, 或者它们适宜的混合溶剂。  In some embodiments, the "acid medium" can be a solid acid system comprising a solid acid as the dispersed or stationary phase and a suitable solvent as the continuous or mobile phase. In the present invention, when referring to a solid acid, it refers to a solid acid, including sulfuric acid, phosphoric acid, boric acid or miscellaneous supported on a carrier of activated carbon, silica, alumina or diatomaceous earth. A polyacid, or an acidic ion exchange resin (such as an acidic ion exchange resin such as 001 x 2 type, 001 x 4 type, 001 x 7 type, or D113 type), which can be used as a dispersed phase or a stationary phase. In the solid acid system, a suitable solvent is also included as a continuous phase or a mobile phase. The solvent in the acid solution and the solid acid system is suitable for the acid solute and the solid acid used, and may be selected from the group consisting of hydrazine, hydrazine-dimercaptoamide, hydrazine, hydrazine-dimercaptoacetamide, hydrazine. - mercapto pyrrolidone, decyl alcohol, ethanol, n-propanol, isopropanol, water, ethylene glycol dioxime ether, tetrahydrofuran, diisopropyl ether, ethyl acetate, acetone, cyclohexanone, trichlorodecane, tetrachloro Decane, disulfoxide, citric acid, acetic acid, or a mixture thereof. Those skilled in the art can routinely select "a solvent suitable for the acid solute used" according to the prior art in the prior art. For example, the selected solvent generally has a certain solubility to the acid solute and the reactant, and under the reaction conditions, Acid solutes do not produce chemical changes that affect the main reaction. In some embodiments, the acid solute is selected from the group consisting of hydrogen chloride, hydrogen bromide, hydrogen iodide, sulfuric acid, or phosphoric acid, or a mixture thereof, and the solvent may be selected from the group consisting of hydrazine, hydrazine-dimercaptoamide, hydrazine, hydrazine-dioxin. Acetamide, fluorenyl-pyridyl pyrrolidone, decyl alcohol, ethanol, n-propanol, isopropanol, water, ethylene glycol dioxime ether, tetrahydrofuran, ethyl acetate, diisopropyl ether, citric acid, acetic acid, etc., or A suitable mixed solvent. In other embodiments, the acid solute is selected from the group consisting of citric acid, acetic acid, sulfonic acid or phthalic acid, or a mixture thereof, and the solvent may be selected from the group consisting of hydrazine, hydrazine-dihydrazinamide, hydrazine, hydrazine- Dimercaptoacetamide, fluorenyl-hydrazinopyrrolidone, water, ethylene glycol dioxime ether, tetrahydrofuran, trichlorodecane, disulfoxide, etc., or a suitable mixed solvent thereof. In other embodiments, the acid solute is selected from the group consisting of sodium hydrogen sulfate, potassium hydrogen sulfate, sodium hydrogen phthalate or potassium hydrogen phthalate, or a compound thereof, and the solvent may be selected from the group consisting of ruthenium, osmium-two. Mercaptoamide, hydrazine, hydrazine-dimercaptoacetamide, fluorenyl-hydrazinopyrrolidone, water, disulfoxide, etc., or a suitable mixed solvent thereof.
在本发明方法的又一些实施方案中,所述酸性介质选自氯化氢的 Ν, Ν-二曱基曱酰胺溶液、 氯化氢的 Ν, Ν-二曱基乙酰胺溶液、 氯化氢 的曱醇溶液、 氯化氢的乙醇溶液、 氯化氢的正丙醇溶液、 盐酸、 氯化 氢的乙酸乙酯溶液、 氯化氢的四氢呋喃溶液、 氢溴酸、 氢碘酸、磷酸 及磷酸水溶液、硫酸水溶液、硫酸曱醇溶液、硫酸乙醇溶液、 多聚磷 酸、 曱酸、 乙酸、 三氟乙酸、 乙酸水溶液和乙酸四氢呋喃溶液, 优选 氯化氢的 Ν, Ν-二曱基曱酰胺溶液、 氯化氢的四氢呋喃溶液、 氯化氢 的曱醇溶液、 氯化氢的乙醇溶液、 盐酸水溶液、 氢溴酸水溶液、硫酸 水溶液、 硫酸曱醇溶液或硫酸乙醇溶液、 或其混合物。 In still other embodiments of the method of the present invention, the acidic medium is selected from the group consisting of hydrazine of hydrogen chloride, hydrazine-dihydrazinamide solution, hydrazine of hydrogen chloride, hydrazine-dimercaptoacetamide solution, sterol solution of hydrogen chloride, hydrogen chloride Ethanol solution, n-propanol solution of hydrogen chloride, hydrochloric acid, ethyl acetate solution of hydrogen chloride, tetrahydrofuran solution of hydrogen chloride, hydrobromic acid, hydroiodic acid, phosphoric acid and phosphoric acid aqueous solution, sulfuric acid aqueous solution, decyl sulfate solution, sulfuric acid ethanol solution, Polyphosphoric acid, citric acid, acetic acid, trifluoroacetic acid, aqueous acetic acid and tetrahydrofuran acetate solution, preferably a solution of hydrogen chloride, a solution of hydrazine-dihydrazinamide, a solution of hydrogen chloride in tetrahydrofuran, a solution of hydrogen chloride in methanol, an aqueous solution of hydrogen chloride, an aqueous solution of hydrochloric acid, an aqueous solution of hydrobromic acid, an aqueous solution of sulfuric acid, a solution of decyl alcohol or a solution of sulfuric acid, or Its mixture.
若在本发明中采用 "液态酸" 或 "酸溶液", 作为酸性介质, 其 用量是本领域技术人员可以常规确定的。例如,其用量可以是反应物 式(III- 0)所示化合物或其盐重量的 2 ~ 40倍,最好是 5 ~ 20倍。 "酸 溶液"中的酸溶质一般相对于式(IV-0)所示化合物过量,最高至该酸 在该溶剂中的饱和量。  If a "liquid acid" or "acid solution" is used in the present invention as an acidic medium, the amount thereof can be conventionally determined by those skilled in the art. For example, it may be used in an amount of from 2 to 40 times, preferably from 5 to 20 times the weight of the compound of the formula (III-0) or a salt thereof. The acid solutes in the "acid solution" are generally in excess relative to the compound of the formula (IV-0), up to the amount of saturation of the acid in the solvent.
在本发明方法的一些优选实施方案中,步骤(a)中式(ΠΙ-0)所示 化合物的"盐"包括但不限于盐酸盐、硫酸盐或氢溴酸盐等。式 (IV-0) 所示化合物的用量相对于 1 摩尔的式 (III- 0)所示化合物或其盐是 1 ~ 10摩尔, 优选 1 ~ 3摩尔。  In some preferred embodiments of the process of the invention, the "salts" of the compounds of formula (?-0) in step (a) include, but are not limited to, hydrochloride, sulfate or hydrobromide, and the like. The compound of the formula (IV-0) is used in an amount of from 1 to 10 mol, preferably from 1 to 3 mol, per mol of the compound of the formula (III-0) or a salt thereof.
在上述反应过程中, 步骤(a)中的反应温度一般是 至介质沸 点,对于常压下挥发性较小的液态酸或酸溶质或固体酸系统,反应温 度可优选室温至溶液沸点,对于挥发性较大的液态酸或酸溶质,反应 温度下限可以是 优选室温, 上限宜低于回流温度。 反应压力优 选为常压,但当需要的反应温度超过介质的常压沸点时,可通过加压 提高其沸点到达或超过所需反应温度。介质在不同压力下的沸点是本 领域常识。  In the above reaction process, the reaction temperature in the step (a) is generally to the boiling point of the medium. For a liquid acid or acid solute or solid acid system which is less volatile under normal pressure, the reaction temperature may preferably be from room temperature to the boiling point of the solution. For larger liquid acids or acid solutes, the lower limit of the reaction temperature may be preferably room temperature, and the upper limit is preferably lower than the reflux temperature. The reaction pressure is preferably atmospheric pressure, but when the required reaction temperature exceeds the atmospheric boiling point of the medium, the boiling point of the medium can be increased to or above the desired reaction temperature by pressurization. The boiling point of the medium at different pressures is common knowledge in the art.
在上述反应过程中, 步骤(a)反应结束时, 得到的产物一般是式 (Π-0)所示化合物与介质中酸形成的酸加成盐,若经过滤或浓缩等后 处理操作, 可直接得到式(Π - 0)所示化合物的酸加成盐; 若经先中 和、再分离的后处理操作,那么就可以得到游离的式(Π- 0)所示化合 物。  In the above reaction process, at the end of the reaction of the step (a), the obtained product is generally an acid addition salt formed by the compound represented by the formula (Π-0) and the acid in the medium, and if subjected to a post-treatment operation such as filtration or concentration, The acid addition salt of the compound of the formula (?-0) can be directly obtained; if the post-treatment is carried out by neutralization and re-separation, a compound of the formula (?-0) can be obtained.
上述反应中, 步骤(b)是任选步骤, 其存在可视需要而定。 若需 将步骤(a)中所得的式(I 1-0)所示化合物的酸加成盐交换成所需的 盐, 或将游离的式(Π- 0)所示化合物制成所需的盐时, 如盐酸盐、硫 酸盐、 氢溴酸盐、磷酸盐、 曱磺酸盐等, 可按本领域内常规的盐交换 技术或成盐技术进行; 若需将步骤 (a)中所得的式(Π- 0)所示化合物 的酸加成盐脱酸变成游离的式(Π-0)所示化合物时,同样可按本领域 内常规的脱酸技术进行。  In the above reaction, the step (b) is an optional step, and the presence thereof may be determined as needed. If desired, the acid addition salt of the compound of the formula (I 1-0) obtained in the step (a) is exchanged to the desired salt, or the compound of the formula (Π-0) is formed into a desired compound. When salt, such as hydrochloride, sulfate, hydrobromide, phosphate, sulfonium sulfonate, etc., can be carried out according to conventional salt exchange techniques or salt formation techniques in the art; if it is to be obtained in step (a) When the acid addition salt of the compound of the formula (?-0) is deacidified to a free compound of the formula (?-0), it can also be carried out according to a conventional deacidification technique in the art.
该制备式(Π- 0)所示化合物或其盐的方法在常规设备中即可顺 利完成, 按照上述的工艺条件, 反应时间一般为 0. 5 ~ 6小时, 比现 有技术的反应时间大大缩短。本发明方法的后处理操作简便,一般可 直接过滤得到产品; 所得产品质量较好 (HPLC纯度一般大于 95%),收 率较高(一般在 60 ~ 90%),一般不需复杂的纯化操作即可直接用于下 一步反应。 The reaction time is generally 0.5 to 6 hours, which is much longer than the prior art. The reaction time is generally 0.5 to 6 hours, which is much longer than the prior art. shorten. The post-treatment of the method of the invention is simple and convenient, generally can be directly filtered to obtain a product; the obtained product has good quality (HPLC purity is generally greater than 95%), and the yield is high (generally 60-90%), generally no complicated purification operation is required. Can be used directly under One step reaction.
在本发明的一些实施方案中,还包括将所得的式(Π- 0)所示化合 物或其盐与式(V- 0 )所示化合物反应,
Figure imgf000008_0001
In some embodiments of the present invention, the method further comprises reacting the obtained compound of the formula (Π-0) or a salt thereof with a compound represented by the formula (V-0),
Figure imgf000008_0001
其中, X代表羟基、 氟、 氯、 溴  Where X represents hydroxy, fluoro, chloro, bromo
R6代表如下式所示的取代基 R 6 represents a substituent represented by the following formula
Figure imgf000008_0002
Figure imgf000008_0002
其中 R7、 R8、 ^和^。各自独立地代表氢、 氟、氯、溴、碘、硝基、Wherein R 7 , R 8 , ^ and ^. Respectively represent hydrogen, fluorine, chlorine, bromine, iodine, nitro,
Cl— 4坑基、 Cl— 4坑^ L¾^、 Cl— 4坑 叛基、 - ( CH坑基 ) Ϊ^、 Cl— 4坑疏基、 d-4烷基亚磺酰基、 d-4烷基磺酰基、 或具有 1-9个选自氟、 氯、 溴、 碘的卤素原子的卤代 -4烷基、 卤代 d-4烷氧基、 卤代 -4烷硫基、 卤 代(^-4烷基亚磺酰基或卤代 d-4烷基磺酰基; Y代表氧、硫、亚磺酰基 或續酰基; Ar代表未取代的或由一个、 两个或多个取代基取代的苯 基、 oc -萘基、 P -萘基、四氢萘基或茚基,其中的取代基选自氟、氯、 溴、 碘、 (^8烷基、 d—8烷氧基、 d—8烷氧 、 二((^-8烷基) J^、 d-8烷硫基、 d-8烷基亚磺酰基、 d-8烷基磺酰基、 具有 1-9个选自氟、 氯、 溴、 碘的相同或不相同卤素原子的卤代 -4烷基、 卤代 d-4烷氧 基、 卤代 d-4烷硫基、 卤代 d-4烷基亚磺酰基或卤代 d-4烷基磺酰基、 具有 3- 7个碳原子的环烷基、 或苯基 d-4烷基、 苯氧基 d-4烷基或苯 氧基, Cl-4 pit foundation, Cl-4 pit ^ L3⁄4^, Cl-4 pit base, - (CH pit base) Ϊ^, Cl-4 pit base, d- 4 alkylsulfinyl, d- 4 alkane arylsulfonyl group, or an 1-9 substituents selected from fluoro, chloro, bromo, iodo halogen atom halo 4 - alkyl, halo-D- 4 alkoxy group, halo --4 alkylthio, halo ( ^ -4 alkylsulfinyl or halo d- 4 alkylsulfonyl; Y represents oxygen, sulfur, sulfinyl or acyl; Ar represents unsubstituted or substituted by one, two or more substituents Phenyl, oc-naphthyl, P-naphthyl, tetrahydronaphthyl or anthracenyl, wherein the substituent is selected from the group consisting of fluorine, chlorine, bromine, iodine, ( 8 alkyl, d- 8 alkoxy, d- 8 alkoxy, di ((^ - 8 alkyl) J ^, d- 8 alkylthio, alkylsulfinyl 8 D-, D- 8 alkylsulfonyl group having 1-9 substituents selected from fluoro, chloro a halogenated 4- alkyl group, a halogenated d- 4 alkoxy group, a halogenated d- 4 alkylthio group, a halogenated d- 4 alkylsulfinyl group or a halogenated group of the same or different halogen atoms of bromine or iodine. d- 4 alkylsulfonyl group, a cycloalkyl group having 3-7 carbon atoms, or a phenyl d- 4 alkyl group, a phenoxy group or a phenoxy group d- 4 ,
制得式(1-0 )所示的化合物,
Figure imgf000008_0003
Producing a compound represented by the formula (1-0),
Figure imgf000008_0003
其中, R,和 R"相互独立地选自氢、 d_2。烷基、 烯基、 C1-2o 炔基、 。环烷基、 。环烷基 。烷基、 C6.1()芳基、 含有 1-3个 杂原子的 4-8元杂环基、 。芳基 。烷基、 。烷氧基 。烷基、 或下式所示基团,
Figure imgf000009_0001
Wherein, R, and R "are each independently selected from hydrogen, d_ 2. Alkyl group, alkenyl group, C 1-2 o alkynyl. Cycloalkyl,. Cycloalkyl. Group, C 6. 1 () An aryl group, a 4-8 membered heterocyclic group having 1 to 3 hetero atoms, an aryl group, an alkyl group, an alkoxy group, an alkyl group, or a group represented by the following formula,
Figure imgf000009_0001
其中 代表氢、 Cwo烷基、 Cwo烯基、 Cwo炔基、 C3.10环烷基 Ci_io坑基、 6-10芳基 Ci_io坑基、 Ci_io坑^ & Ci_io坑基; R 、 R3和Wherein represents hydrogen, Cwo alkyl, Cwoalkenyl, Cwo alkynyl, C 3 .10 cycloalkyl Ci_io pit, 6-10 aryl Ci_io pit, Ci_io pit ^ & Ci_io pit; R, R3 and
R4相互独立地选自氢、 氟、 氯、 溴、碘、 d_2。烷基、 烯基、 C1-2o 块基、 Ci_20坑 &、 C3-IO环坑基、 C3-IO环坑基 Ci_io坑基、 C6-10芳基、 c6.10芳基 烷基、 cM0烷 C o烷基。该反应的实施和式(V- 0) 所示化合物的制备均可参照 US4956370 中公开的方法进行。 R 4 is independently selected from the group consisting of hydrogen, fluorine, chlorine, bromine, iodine, and d_ 2 . Alkyl, alkenyl, C 1-2 o block, Ci_20 pit &, C3-IO ring pit, C3-IO ring pit based Ci_io pit group, C6-10 aryl, c 6 .10 arylalkyl, c M0 alkane C o alkyl. The practice of the reaction and the preparation of the compound of formula (V-0) can be carried out in accordance with the process disclosed in U.S. Patent 4,956,370.
US4956370的全文通过引用并入本文。 The entire disclosure of US 4,956,370 is incorporated herein by reference.
在本发明方法的一些具体实施方案中, 在式(V- 0 )和式(1-0 ) 中, R6代表如下式所示的取代基 In some specific embodiments of the method of the present invention, in the formula (V-0) and the formula (1-0), R 6 represents a substituent represented by the following formula
Figure imgf000009_0002
Figure imgf000009_0002
其中, R7、 R8、 !^和^。各自独立地代表氢、 氟、 氯、 溴、 碘、 硝 基、 曱基、 乙基、 曱氧基、 乙氧基、 曱氧基 ^ &、 乙氧基 ^ &、 二曱 基 ^、 二乙基 ^&、 曱硫基、 乙硫基、 曱烷基亚磺酰基、 乙烷基亚 磺酰基、 曱基磺酰基、 乙基磺酰基、 或具有 1-5个选自氟、 氯、 溴、 碘的相同或不相同卤素原子的卤代曱基、 卤代乙基、 卤代曱氧基、 卤 代乙氧基、 卤代曱硫基、 卤代乙硫基、 卤代曱基亚磺酰基、 卤代乙基 亚磺酰基、 卤代曱基磺酰基或卤代乙基磺酰基, 优选地为氢、 曱基、 乙基、 曱 L &、 乙氧基; X代表氧、 硫、 亚磺酰基或磺酰基, 优选地 为氧; Ar代表未取代的或由一个、 两个或多个取代基取代的苯基、 a -萘基、 P -萘基、四氢萘基或茚基,其中的取代基选自氟、氯、溴、 碘、 (^-6烷基、 (^-6烷氧基、 d—6烷氧羰基、 二((^-6烷基)氨基、 d-3 烷硫基、 d-3烷基亚磺酰基、 d-3烷基磺酰基、具有 1-7个选自氟、氯、 溴、 碘的相同或不同卤素原子的卤代 d-3烷基、 卤代 -3烷硫基、 卤 代 d-3烷基亚磺酰基或卤代 d-3烷基磺酰基、 具有 3-7个^^子的环 烷基、 或苯基 d-3烷基、 苯氧基 d-3烷基或苯氧基, 优选地为苯基、 2-曱基苯基、 4-曱基苯基、 2, 6-二曱基苯基、 2, 4-二曱基苯基、 2, 4, 6- 三曱基苯基、 a -萘基、 β -萘基、 四氢萘基或茚基。 在本发明更具体的实施方案中,式(I 1-0)所示化合物或其盐是式 (II)所示的化合物或其盐, 式( V- 0 )所示化合物是式( V )或式( VI ) 所示的化合物, 并且式 (1-0)所示化合物或其盐是式( I )所示化合 物或其盐。 Among them, R 7 , R 8 , ! ^ and ^. Each independently represents hydrogen, fluorine, chlorine, bromine, iodine, nitro, decyl, ethyl, decyloxy, ethoxy, decyloxy, ethoxy^, bismuth, and diethyl Or thiol, ethylthio, decylsulfinyl, ethanesulfinyl, decylsulfonyl, ethylsulfonyl, or having from 1 to 5 selected from fluorine, chlorine, bromine, Halogenated fluorenyl, haloethyl, halodecyloxy, haloethoxy, halothiol, haloethylthio, halodecylsulfinyl having the same or different halogen atoms of iodine , haloethylsulfinyl, halosulfonylsulfonyl or haloethylsulfonyl, preferably hydrogen, fluorenyl, ethyl, 曱L &ethoxy; X represents oxygen, sulfur, sulfin An acyl or sulfonyl group, preferably an oxygen; Ar represents a phenyl group, a-naphthyl group, P-naphthyl group, tetrahydronaphthyl group or anthracenyl group which is unsubstituted or substituted by one, two or more substituents, wherein The substituent is selected from the group consisting of fluorine, chlorine, bromine, iodine, (^- 6 alkyl, (^ -6 alkoxy, d- 6 alkoxycarbonyl, bis((^- 6 alkyl)amino, d- 3 alkane) group, d- 3 Alkylsulfinyl, d- 3 alkylsulfonyl group, having the same or different halogen atoms, haloalkyl of 1-7 substituents selected from fluoro, chloro, bromo, iodo d-3 alkyl, halo --3 alkylthio, Halogenated d- 3 alkylsulfinyl or halo d- 3 alkylsulfonyl, cycloalkyl having 3-7, or phenyl d-3 alkyl, phenoxy d-3 Or phenoxy, preferably phenyl, 2-nonylphenyl, 4-nonylphenyl, 2,6-didecylphenyl, 2,4-didecylphenyl, 2, 4, 6-trimethylphenyl, a-naphthyl, β-naphthyl, tetrahydronaphthyl or anthracenyl. In a more specific embodiment of the present invention, the compound of the formula (I 1-0) or a salt thereof is a compound of the formula (II) or a salt thereof, and the compound of the formula (V-0) is a formula (V) Or a compound represented by the formula (VI), and the compound of the formula (1-0) or a salt thereof is a compound of the formula (I) or a salt thereof.
Figure imgf000010_0001
Figure imgf000010_0001
以上所有方法中反应的适宜时间是本领域普通技术人员根据所 知道的常规法可以确定的, 例如由常规层析及光谱技术(如 TLC和 HPLC)监测反应的进程来确定。  Suitable times for the reaction in all of the above methods can be determined by one of ordinary skill in the art in accordance with conventional methods known, for example, by monitoring the progress of the reaction by conventional chromatography and spectroscopy techniques such as TLC and HPLC.
在一些上述通式 (1-0)、(Π- 0)和(III- 0) 化合物的结构中具有 氢化氨基嘧啶环部分。例如,在化合物(1)、 (Π)和(ΙΠ)的结构中均 具有氢化氨基嘧啶环部分,因此它们中的每一个化合物都可能以其互 变异构体的平衡混合物形式存在,下列的局部结构式表示分子中进行 互变异构的那部分结构,  There are hydrogenated aminopyrimidine ring moieties in the structures of some of the above compounds of the formulae (1-0), (Π-0) and (III-0). For example, in the structures of the compounds (1), (Π) and (ΙΠ), there are hydrogenated aminopyrimidine ring moieties, and therefore each of them may exist as an equilibrium mixture of its tautomers, the following The local structural formula represents the part of the structure in which the tautomerism is carried out,
Figure imgf000010_0002
Figure imgf000010_0002
为了叙述的方便, 在本说明书中仅就互变异构体中 "(1,4,5,6- 四氢- 2-嘧 ) J^"以及其相关的名称进行了讨论, 但应当理解, 这样的描述包括相应的互变 "(六氢- 2-嘧啶基)亚氨基"、 "(3,4,5,6- 四氢- 2-嘧啶基)氨基" 等形式。  For the convenience of description, only "(1,4,5,6-tetrahydro-2-pyrimidine) J^" and its related names in the tautomers are discussed in the present specification, but it should be understood that Such description includes the corresponding interconversion "(hexahydro-2-pyrimidinyl)imino", "(3,4,5,6-tetrahydro-2-pyrimidinyl)amino" and the like.
对于(1, 4, 5, 6-四氢- 2-嘧啶基)硫脲 (II)的结构, 除了氢化氨基 嘧啶环部分有互变异构现象外,其硫脲部分也有互变异构现象, 因此 化合物(Π)可能以如下所示的互变异构体的平衡混合物形式存在。 For the structure of (1, 4, 5, 6-tetrahydro-2-pyrimidinyl) thiourea (II), in addition to the tautomerization of the hydrogenated aminopyrimidine moiety, the thiourea moiety also has tautomerism. So The compound (Π) may exist as an equilibrium mixture of tautomers as shown below.
Figure imgf000011_0001
同样, 为了叙述的方便, 在本说明书中仅就互变异构体中 " (1, 4, 5, 6-四氢- 2-嘧¾^)硫脲"的名称进行了讨论,但应当理解, 这样的描述包括其它的互变形式。
Figure imgf000011_0001
Similarly, for the convenience of description, only the name of "(1, 4, 5, 6-tetrahydro-2-pyribyl) thiourea" in the tautomer is discussed in this specification, but it should be understood Such description includes other mutual deformations.
综上所述,本发明提供了制备式( Π-0 )所示硫脲化合物的方法, 该方法革除了现有技术中的剧毒恶臭硫化氢,而且大大缩短了反应时 间, 提高了生产效率, 简化了后处理过程。 另外, 本方法操作简便, 所有操作在常规反应设备中即可完成, 所得产品质量好, 收率高, 利 于产业化生产。 在此基础上, 本发明进一步将该方法应用于制备 2- 噻唑类化合物(如式 1-0所示), 特别是阿巴芬净(1)。 具体实施方式  In summary, the present invention provides a method for preparing a thiourea compound represented by the formula (?-0), which eliminates the highly toxic malodorous hydrogen sulfide in the prior art, and greatly shortens the reaction time and improves the production efficiency. , simplifies the post-processing process. In addition, the method is simple and convenient to operate, and all operations can be completed in conventional reaction equipment, and the obtained product has good quality and high yield, which is favorable for industrial production. On the basis of this, the present invention further applies the method to the preparation of a 2-thiazole compound (as shown in Formula 1-0), particularly abifene (1). Detailed ways
下面将结合实施例对本发明作进一步说明。提供这些实施例的目 的仅在于举例说明, 它们不以任何方式限制本发明的范围。 实施例中 使用的术语和缩写具有通常的含义。如 "L"、 "g"、 "mol"、 " % ( g/g )"、 "ml"、 "^C"、 "TLC"、 "h"、 "HPLC"、 "Mp"、 "IR"、 " (+) ESI- MS"、 ttlH NMR" 分别是指升、 克、 摩尔、 质量百分比、 毫升、 摄氏度、 薄层色 谱、 小时、 高效液相色谱、 熔点、 红外吸收光谱、 正离子方式电喷雾 离子源质谱、质子核磁共振。 在核磁共振数据中, "s"代表单峰, "d" 代表双重峰, "t"代表三重峰, "quintet"代表五重峰, "dd"代表 双重双峰, "m"代表多重峰。 实施例 1 The invention will now be further described in connection with the examples. The examples are provided for the purpose of illustration only, and are not intended to limit the scope of the invention in any way. The terms and abbreviations used in the examples have the usual meanings. Such as "L", "g", "mol", "% (g/g)", "ml", "^C", "TLC", "h", "HPLC", "Mp", "IR" , "(+) ESI-MS", ttl H NMR" means liter, gram, mole, mass percentage, cc, Celsius, TLC, H, HPLC, melting point, infrared absorption spectrum, positive ion mode Electrospray ionization mass spectrometry, proton nuclear magnetic resonance. In NMR data, "s" stands for single peak, "d" stands for doublet, "t" stands for triplet, "quintet" stands for five peak, "dd" stands for double Double peak, "m" stands for multiple peaks. Example 1
(1, 4, 5, 6-四氢- 2-嘧<¾&)硫脲(Π)盐酸盐的制备  Preparation of (1, 4, 5, 6-tetrahydro- 2-pyrimidine <3⁄4&) thiourea (hydrazine) hydrochloride
在 3L 三口瓶中, 加入(1, 4, 5, 6-四氢- 2-嘧啶基)氨基腈(III) 124. Og (l. Omol) , 硫代乙酰胺(IV) 113. Og (1. 5mol)和约 10% (g/g)的 氯化氢 /Ν, Ν-二曱基曱酰胺溶液 1000ml, 在 80 ~ 下反应至原料 (1, 4, 5, 6-四氢- 2-嘧^) 消失(TLC监测反应进程, 展 开剂: 乙酸乙酯:曱醇 = 10: 1 ), 耗时约 2h。待反应液冷却后, 过滤, 滤饼干燥后得标题化合物 182. 6g,白色固体。 HPLC: 98.66%; Og (1. 4 mol, thioacetamide (IV) 113. Og (1) 5mol) and about 10% (g/g) of hydrogen chloride / hydrazine, 1000 ml of hydrazine-dihydrazinamide solution, reacted at 80 ~ to the starting material (1, 4, 5, 6-tetrahydro- 2-pyrimidine) Disappeared (TLC monitors the progress of the reaction, developing solvent: ethyl acetate: decyl alcohol = 10:1), which takes about 2 hours. After the reaction mixture was cooled, the title compound was obtained. HPLC: 98.66%;
Mp: 183 - 1851C;  Mp: 183 - 1851C;
IR(KBr): 3140, 3022, 1687, 1637, 1603, 1573, 1402, 1333 1304, 1055, 986, 961, 686 cm"1: 实施例 2 IR (KBr): 3140, 3022, 1687, 1637, 1603, 1573, 1402, 1333 1304, 1055, 986, 961, 686 cm" 1 : Example 2
(1, 4, 5, 6-四氢- 2-嘧^)硫脲(II)的制备  Preparation of (1, 4, 5, 6-tetrahydro- 2-pyrimidine) thiourea (II)
在 2L三口瓶中, 加入实施例 1中得到的(1,4, 5, 6-四氢- 2-嘧啶 基)硫脲 (II)盐酸盐 100.0g, 10% (g/g)的碳酸钠水溶液 750ml,在 40 ~ 45°C下搅拌 0.5h,冷却,过滤,滤饼干燥后得标题化合物 (II) 76.5g, 白色固体。  In a 2 L three-necked flask, 100.0 g of (1,4,5,6-tetrahydro-2-pyrimidinyl)thiourea (II) hydrochloride obtained in Example 1 was added, and 10% (g/g) of carbonic acid was added. 750 ml of a sodium aqueous solution was stirred at 40 to 45 ° C for 0.5 h, cooled, filtered, and filtered to give the title compound (II) 76.5 g.
HPLC: 99.25%;  HPLC: 99.25%;
Mp: 173 - 175 C;  Mp: 173 - 175 C;
IR(KBr): 3424, 3301, 3104, 3028, 2967, 2870, 1615, 1590, 1457, 1420, 1374, 1324, 1171, 1079, 905, 736, 656 cm—1; IR (KBr): 3424, 3301, 3104, 3028, 2967, 2870, 1615, 1590, 1457, 1420, 1374, 1324, 1171, 1079, 905, 736, 656 cm- 1 ;
(+) ESI-MS: 159(M+1)。 实施例 3  (+) ESI-MS: 159 (M+1). Example 3
(1, 4, 5, 6-四氢- 2-嘧^)硫脲(II)的制备  Preparation of (1, 4, 5, 6-tetrahydro- 2-pyrimidine) thiourea (II)
在 2L 三口瓶中, 加入(1,4, 5, 6-四氢- 2-嘧啶基)氨基腈(III) In a 2L three-necked flask, add (1,4,5,6-tetrahydro-2-pyrimidinyl) aminonitrile (III)
124.0g(l. Omol)、硫代乙酰胺(IV) 90.0g(l.2mol)和常压下饱和的氯 化氢 /四氢呋喃溶液 1000ml, 在 45 ~ 501C下常压反应至原料 (1, 4, 5, 6-四氢- 2-嘧^) (III)消失( TLC监测反应进程, 展 开剂: 乙酸乙酯:曱醇 =10: 1), 耗时约 4h。 加入约 20% (g/g)的氢氧 化钠水溶液调反应液 pH至 8左右, 过滤, 滤饼干燥后得标题化合物 (11)143.5g,白色固体。 124.0 g (1.0 mol), thioacetamide (IV) 90.0 g (1.2 mol) and 1000 ml of a saturated hydrogen chloride/tetrahydrofuran solution under normal pressure, and reacted at a normal pressure of 45 to 501 C to a raw material (1, 4, 5) , 6-tetrahydro- 2-pyrimidine) (III) disappeared (TLC monitors the progress of the reaction, developing solvent: ethyl acetate: decyl alcohol = 10:1), which took about 4 hours. Approximately 20% (g/g) of aqueous sodium hydroxide solution was added to adjust the pH of the mixture to pH </ RTI> </ RTI> </ RTI> <RTIgt;
HPLC: 98.30%;  HPLC: 98.30%;
Mp: 172 - 174^C;  Mp: 172 - 174^C;
IR(KBr): 3425, 3301, 3105, 3028, 2967, 2870, 1618, 1591, 1458, 1422, 1374, 1323, 1172, 1078, 905, 735, 657 cm—1; IR (KBr): 3425, 3301, 3105, 3028, 2967, 2870, 1618, 1591, 1458, 1422, 1374, 1323, 1172, 1078, 905, 735, 657 cm- 1 ;
XH NMR (400MHz, CDC13) δ (ppm): 1.97 - 2.03 (2H, quintet) , 3.43 - 3.46 (4H, t) ; X H NMR (400 MHz, CDC1 3 ) δ (ppm): 1.97 - 2.03 (2H, quintet), 3.43 - 3.46 (4H, t);
(+) ESI-MS: 159(M+1)。 实施例 4 ~ 实施例 13  (+) ESI-MS: 159 (M+1). Embodiment 4 ~ Embodiment 13
按上述实施例 3的操作, 在下表所示条件下制得(1, 4, 5, 6-四氢 -2-嘧啶基)硫脲(Π), 所用反应均在常压下进行。 According to the operation of Example 3 above, (1, 4, 5, 6-tetrahydrogen was produced under the conditions shown in the table below. 2-pyrimidinyl)thiourea (Π), the reactions used were all carried out under normal pressure.
Figure imgf000013_0001
Figure imgf000013_0001
实施例 14  Example 14
N- [4- [2- (2, 4-二曱基苯氧基)苯基] -2-噻唑基] -1, 4, 5, 6-四氢 -2-嘧啶胺 (I)盐酸盐的制备  N-[4-[2-(2,4-Dimercaptophenoxy)phenyl]-2-thiazolyl]-1,4,5,6-tetrahydro-2-pyrimidinamine (I) Hydrochloric acid Preparation of salt
在 1L 反应瓶中, 加入(1,4, 5, 6-四氢- 2-嘧啶基)硫脲(Π) 79.0g(0.5mol)、 2 -氯- 1- [2- (2, 4-二曱基苯氧基)苯基]乙酮(V) 137.5g(0.5mol)和丙酮 600ml,常压下加热回流反应至原料消失( TLC 监测反应进程, 展开剂: 乙酸乙酯:曱醇 =10: 1), 耗时约 5h; 冷却, 过滤, 用适量丙酮洗滤饼, 滤饼干燥后得标题化合物 172.3g, 类白 色固体。  In a 1 L reaction flask, (1,4,5,6-tetrahydro-2-pyrimidinyl)thiourea (Π) 79.0 g (0.5 mol), 2-chloro-1- [2- (2, 4-) Dimethylphenol oxy)phenyl]ethanone (V) 137.5 g (0.5 mol) and acetone 600 ml, heated under reflux at normal pressure until the starting material disappeared (TLC monitoring reaction progress, developing solvent: ethyl acetate: decyl alcohol = 10: 1), consuming about 5 h; cooling, filtration, washing the cake with an appropriate amount of acetone, and the filter cake was dried to give the title compound 172.3 g.
HPLC: 97.52%  HPLC: 97.52%
Mp: 161~163 实施例 15 Mp: 161~163 Example 15
N- [4- [2- (2, 4-二曱基苯氧基)苯基] -2-噻唑基] -1, 4, 5, 6-四氢 -2-嘧啶胺 (I)氢溴酸盐的制备  N-[4-[2-(2,4-Dimercaptophenoxy)phenyl]-2-thiazolyl]-1,4,5,6-tetrahydro-2-pyrimidinamine (I) Hydrobromo Preparation of acid salt
在 1L 反应瓶中, 加入(1,4, 5, 6-四氢- 2-嘧啶基)硫脲(Π) 79.0g(0.5mol) , 2-溴- 1- [2- (2, 4-二曱基苯氧基)苯基〗 乙酮 (VI) 160.0g(0.5mol)和丙酮 600ml,常压下加热回流反应至原料消失 (TLC监测反应进程, 展开剂: 乙酸乙酯:曱醇 =10: 1), 耗时约 3h; 冷却, 过滤, 用适量丙酮洗滤饼, 滤饼干燥后得标题化合物 211.7g, 类白色固体。  In a 1 L reaction flask, (1,4,5,6-tetrahydro-2-pyrimidinyl)thiourea (Π) 79.0 g (0.5 mol), 2-bromo-1- [2- (2, 4-) Dimethyl phenoxy)phenyl ketone Ethyl ketone (VI) 160.0g (0.5mol) and acetone 600ml, heated under reflux at normal pressure until the starting material disappears (TLC monitoring reaction progress, developing solvent: ethyl acetate: decyl alcohol = 10: 1), consuming about 3 h; cooling, filtration, washing the cake with an appropriate amount of acetone, and the filter cake was dried to give the title compound 211.7 g.
HPLC: 98.74%;  HPLC: 98.74%;
Mp: 212-214 C;  Mp: 212-214 C;
实施例 16  Example 16
N- [4- [2- (2, 4-二曱基苯氧基)苯基〗 -2-噻唑基] -1, 4, 5, 6-四氢 N-[4- [2-(2,4-Dimercaptophenoxy)phenyl]-2-thiazolyl]-1,4,5,6-tetrahydro
-2 -嘧 α)的制备 Preparation of -2 -pyrimidine α)
在 5L反应瓶中,加入实施例 14中所得的 Ν- [4- [2- (2,4-二曱基 苯氧基)苯基] -2-噻唑基 ]-1,4, 5, 6-四氢- 2-嘧啶胺(Π)盐酸盐 100.0g、 加入乙醇 1000ml, 在 60 ~ 65°C下加热溶清, 加入 1%氢氧化 钠溶液 2000ml, 再在室温下搅拌 2h, 过滤, 用适量水洗滤饼, 滤饼 干燥后得标题物 83.5g, 类白色晶体。  In the 5 L reaction flask, Ν-[4-[2-(2,4-dimercaptophenoxy)phenyl]-2-thiazolyl]-1,4,5,6 obtained in Example 14 was added. -100.0g of tetrahydro-2-pyrimidinamine hydrochloride, adding 1000ml of ethanol, heating and dissolving at 60 ~ 65 ° C, adding 2000ml of 1% sodium hydroxide solution, stirring at room temperature for 2h, filtering, The filter cake was washed with an appropriate amount of water, and the cake was dried to give the title compound (83.5 g, white crystals).
HPLC: 99.08%;  HPLC: 99.08%;
Mp: 194 - 196^;  Mp: 194 - 196^;
IR (KBr): 3215, 3038, 2961, 2859, 1637, 1565, 1492, 1478, 1459, 1449, 1437, 1376, 1348, 1319, 1277, 1250, 1219, 1146, 1122, 1061, 858, 818, 763, 745, 728, 707, 649 cm—1; IR (KBr): 3215, 3038, 2961, 2859, 1637, 1565, 1492, 1478, 1459, 1449, 1437, 1376, 1348, 1319, 1277, 1250, 1219, 1146, 1122, 1061, 858, 818, 763 , 745, 728, 707, 649 cm- 1 ;
XH NMR (400MHz, CDC13) δ (ppm): 1.95-2.01 (2H, quintet) ,XH NMR (400MHz, CDC1 3 ) δ (ppm): 1.95-2.01 (2H, quintet),
2.21(3H, s), 2.31 (3H, s), 3.44 ~ 3.46 (4H, t), 6.68 ~ 6.70 (1H, dd) , 6.79- 6.81 (1H, d) , 6.94 - 6.97 (1H, dd) , 7.07 ~ 7.15 (3H, m), 7.23 (1H, s), 7.99-8.01 (1H, m) ; 2.21(3H, s), 2.31 (3H, s), 3.44 ~ 3.46 (4H, t), 6.68 ~ 6.70 (1H, dd), 6.79- 6.81 (1H, d), 6.94 - 6.97 (1H, dd) , 7.07 ~ 7.15 (3H, m), 7.23 (1H, s), 7.99-8.01 (1H, m) ;
(+) ESI-MS: 379 (M+1)。  (+) ESI-MS: 379 (M+1).
按上述方法, 用实施例 15中所得的 N- [4- [2- (2,4-二曱基苯氧 基)苯基〗 -2-噻唑基] -1, 4, 5, 6-四氢- 2-嘧啶胺 (I I)氢溴酸盐同样可 得标题化合物。  N-[4-[2-(2,4-dimercaptophenoxy)phenyl]-2-thiazolyl]-1, 4, 5, 6-tetra which was obtained in Example 15 as described above. The title compound can also be obtained from the hydrogen-2-pyrimidinamine (II) hydrobromide salt.
本发明方法革除了现有技术中的剧毒恶臭硫化氢,而且大大缩短 了反应时间, 提高了生产效率, 简化了反应和后处理过程。 另外, 本 方法操作简便,可在常规反应设备中完成,所得产品质量好,收率高, 利于产业化生产。  The method of the invention eliminates the highly toxic malodorous hydrogen sulfide in the prior art, and greatly shortens the reaction time, improves the production efficiency, and simplifies the reaction and the post-treatment process. In addition, the method is simple and convenient to operate, and can be completed in a conventional reaction equipment, and the obtained product has good quality and high yield, which is favorable for industrial production.

Claims

权 利 要 求  Rights request
-种制备式(Π-0 )所示化合物或其盐的方法,
Figure imgf000015_0001
a method for preparing a compound of the formula (Π-0) or a salt thereof,
Figure imgf000015_0001
其中, R,和 R"相互独立地选自氢、 d_2。烷基、 烯基、 C1-2o 炔基、 C3.io环烷基、 C3.io环烷基 CM0烷基、 C6.10芳基、 含有 1-3个杂原子的 4-8元杂环基、 。芳基 d.w烷基、 。烷氧 基 烷基、 或下式所示的基团, Wherein, R, and R "are each independently selected from hydrogen, d_ 2. Alkyl group, alkenyl group, C 1-2 o alkynyl, C 3 .io cycloalkyl, C 3 .io alkyl cycloalkyl C M0 a C 6 .10 aryl group, a 4-8 membered heterocyclic group having 1 to 3 hetero atoms, an aryl dw alkyl group, an alkoxyalkyl group, or a group represented by the following formula,
Figure imgf000015_0002
Figure imgf000015_0002
其中 代表氢、 烷基、 烯基、 炔基、 C3-1。环烷 基 C _io坑基、 C6_10芳基 C _io坑基、 坑 基 坑基; R 、It represents hydrogen, alkyl, alkenyl, alkynyl, C 3-1 . Cycloalkyl C _io pit group, C6_10 aryl C _io pit base, pit foundation pit; R ,
R3和 Rt相互独立地选自氢、 氟、 氯、 溴、碘、 烷基、 C1-2o 婦基、 C -20块基、 C -20坑 基、 C3-IO环坑基、 C3-IO环坑基 C -io 坑基、 C6-10芳基、 C6-10芳基 Ci-io坑基、 Ci-io坑 基 Ci-io坑基, 该方法包括: R 3 and Rt are independently selected from the group consisting of hydrogen, fluorine, chlorine, bromine, iodine, alkyl, C 1-2 o, C -20, C -20, C 3 - 10 ring, C 3 -IO ring pit base C -io pit base, C6-10 aryl group, C6-10 aryl Ci-io pit base, Ci-io pit base Ci-io pit base, the method includes:
(a)将式 (III-O)所示化合物或其盐  (a) a compound of the formula (III-O) or a salt thereof
R'- -N-  R'- -N-
R" ( III-0 ) R" ( III-0 )
其中, R,和 R"的定义同上, Where R, and R" are as defined above,
在适宜的酸性介质中与式 (IV-0)所示化合物反应制得式 (11-0) 所示化合物或其相应的酸加成盐,
Figure imgf000016_0001
(ΐν-0)
The compound of the formula (11-0) or its corresponding acid addition salt is obtained by reacting with a compound of the formula (IV-0) in a suitable acidic medium.
Figure imgf000016_0001
(ΐν-0)
其中, R5代表 d.20烷基、 d.20烯基、 Cwo炔基、 C3.10环烷基Wherein R 5 represents d.20 alkyl, d.20 alkenyl, Cwo alkynyl, C 3 .10 cycloalkyl
Ci_io坑基、 C6-io芳基 Ci_io坑基、 Ci_io坑 Ci_io坑基; 和 (b)任选地, 将步骤 (a)得到的式 (II-0)所示化合物或其酸加成盐 转化成所需的盐或将步骤 (a)得到的式 (Π-0)所示化合物的酸加 成盐脱酸成游离的式 (11-0)所示化合物。 a Ci_io pit group, a C6-ioaryl Ci_io pit group, a Ci_io pit Ci_io pit group; and (b) optionally, converting the compound of the formula (II-0) obtained in the step (a) or an acid addition salt thereof The desired salt or the acid addition salt of the compound of the formula (?-0) obtained in the step (a) is deacidified to the compound of the formula (11-0).
、 根据权利要求 1的方法, 其中在式( 11-0 )和式( III-0 )中, R, 和 R"相互独立地选自氢、 d.w烷基、 。烯基、 。块基、 C3.8环烷基、 C3.8环烷基 d.6烷基、 C6.8芳基、 含有 1-2个杂原 子的 5-6元杂环基、 C6.8芳基 d.6烷基、 d.6烷氧基 d.6烷基、 或下式所示基团, The method according to claim 1, wherein in the formula (11-0) and the formula (III-0), R, and R" are independently selected from hydrogen, dw alkyl, alkenyl, block, C 3.8 cycloalkyl, C 3.8 cycloalkyl, d. 6 alkyl, C 6. 8 aryl, 5-6 membered heterocyclyl contains 1-2 heteroatoms, C 6. 8 aryl group d a 6 alkyl group, a d. 6 alkoxy group, a d. 6 alkyl group, or a group represented by the following formula,
Figure imgf000016_0002
Figure imgf000016_0002
其中, ^代表氢、 。烷基、 。烯基、 。炔基、 c3.7环烷 基 C _6坑基、 C6_8芳基 C _6坑基、 Ci_6坑 C 6坑基; R 、Where ^ represents hydrogen, . Alkyl, . Alkenyl, . Alkynyl, c 3. 7 cycloalkyl C -6 pit group, C6_8 aryl C _ 6 pit group, Ci_6 pit C 6 pit base; R ,
R3和 Rt相互独立地选自氢、 氟、 氯、 溴、碘、 Cw。烷基、 CM0 烯基、 CMO炔基、 CMO烷 L &、 C3-7环烷基、 C3-7环烷基 Ci.6 坑基、 C6-8芳基、 C6-8芳基 Ci_6坑基、 C _6坑 基 C _6坑基; 在式(IV-0 ) 中, R5代表( ^烷基、 Cwo烯基、 d. 炔基、R 3 and Rt are independently of each other selected from the group consisting of hydrogen, fluorine, chlorine, bromine, iodine, and C w . Alkyl, C M0 alkenyl, CMO alkynyl, CMO alkane L &, C 3 -7 cycloalkyl, C 3 -7 cycloalkyl Ci. 6 pit, C6-8 aryl, C6-8 aryl Ci_6 Pit basis, C _6 pit base C _6 pit base; in formula (IV-0 ), R 5 represents (^ alkyl, Cwo alkenyl, d. alkynyl,
C3-7环坑 Ci_6坑¾^、 C6-8芳 Ci_6坑¾^、 Cl- ¾-?LS^ Cl-坑&。 、 根据权利要求 1的方法, 其中在式( 11-0 )和式( III-0 )中, R, 和 R"中的一个为氢, 另一个为氢、 d_6烷基、 d_6烯基、 Ci.6 炔基、 C3.6环烷基、 C3.6环烷基 d.6烷基、 C6-7芳基、或下式所 示基团, C3-7 ring pit Ci_6 pit 3⁄4^, C6-8 Fang Ci_6 pit 3⁄4^, Cl- 3⁄4-?LS^ Cl-pit &. The method according to claim 1, wherein in the formula (11-0) and the formula (III-0), one of R, and R" is hydrogen, and the other is hydrogen, d- 6 alkyl, d- 6 alkenyl , Ci. 6 ... An alkynyl group, C 3 6 cycloalkyl, C 3 6 cycloalkyl d 6 alkyl, C 6 - 7 aryl group, or a group represented by the following formula,
Figure imgf000017_0001
Figure imgf000017_0001
其中, 代表氢、 d_6烷基; R2、 R3和 Rt相互独立地选自氢、 氟、 氯、 d.6烷基、 d.6烷氧基; Wherein, represents hydrogen, d 6 alkyl; R 2 , R 3 and Rt are, independently of each other, selected from the group consisting of hydrogen, fluorine, chlorine, d. 6 alkyl, d. 6 alkoxy;
在式(IV-0) 中, R5代表曱基、 乙基、 正丙基、 异丙基、 正丁 基、 异丁基、 正戊基、 异戊基、 正己基、 正辛基或 2-乙基己基。 、 根据权利要求 1的方法, 其中式(11-0)所示的化合物是式 (II) 所示的化合物, 式(III-0)所示的化合物是式 (III)所示的化合 物, 并且式(IV-0)所示的化合物是式 (IV)所示的化合物, In formula (IV-0), R 5 represents decyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, n-pentyl, isopentyl, n-hexyl, n-octyl or 2 -ethylhexyl. The method according to claim 1, wherein the compound represented by the formula (11-0) is a compound represented by the formula (II), the compound represented by the formula (III-0) is a compound represented by the formula (III), and The compound represented by the formula (IV-0) is a compound represented by the formula (IV).
Figure imgf000017_0002
H3C 、: H2
Figure imgf000017_0002
H 3 C ,: H 2
(II) (III) (IV) 。 根据权利要求 1-4任何一项所述的方法, 其中在步骤 ) 中 形成的是式(Π-0)所示化合物的酸加成盐。 (II) (III) (IV). The method according to any one of claims 1 to 4, wherein in the step), an acid addition salt of a compound of the formula (?-0) is formed.
、 根据权利要求 5的方法, 其中在步骤 ) 中, 所述式(11-0) 所示化合物的酸加成盐经冷却析出、 过滤和任选地干燥, 以便 得到该酸加成盐。 The method according to claim 5, wherein in the step, the acid addition salt of the compound of the formula (11-0) is cooled, precipitated, and optionally dried to obtain the acid addition salt.
根据权利要求 1 - 4任何一项所述的方法,其中所述酸性介质是 液态酸、 酸溶液或固体酸系统。 、 根据权利要求 7所述的方法, 其中所述液态酸是磷酸、 多聚磷 酸、 曱酸、 乙酸、 曱磺酸、 三氟乙酸, 或它们适宜的混合物; 酸溶液中酸溶质是氯化氢、 溴化氢、 碘化氢、 硫酸、 磷酸、 硫 酸氢钠、 硫酸氢钾、 曱酸、 乙酸、 曱磺酸、 邻苯二曱酸、 邻苯 二曱酸氢钠、 邻苯二曱酸氢钾, 或它们适宜的混合物; 酸溶液 中溶剂与所用酸溶质相适应, 选自下列物质: N,N-二曱基曱酰 胺、 N,N-二曱基乙酰胺、 N-曱基吡咯烷酮、 曱醇、 乙醇、 正丙 醇、 异丙醇、 水、 乙二醇二曱醚、 四氢呋喃、 异丙醚、 乙酸乙 酯、 丙酮、 环己酮、 三氯曱烷、 四氯曱烷、 二曱亚砜、 曱酸、 乙酸, 或它们适宜的混合物。 A method according to any one of claims 1 to 4, wherein the acidic medium is a liquid acid, an acid solution or a solid acid system. The method according to claim 7, wherein the liquid acid is phosphoric acid, polyphosphoric acid, citric acid, acetic acid, hydrazine sulfonic acid, trifluoroacetic acid, or a suitable mixture thereof; the acid solute in the acid solution is hydrogen chloride, bromine Hydrogen, hydrogen iodide, sulfuric acid, phosphoric acid, sodium hydrogen sulfate, potassium hydrogen sulfate, citric acid, acetic acid, sulfonic acid, phthalic acid, sodium hydrogen phthalate, potassium hydrogen phthalate, Or a suitable mixture thereof; the solvent in the acid solution is compatible with the acid solute used, and is selected from the group consisting of N,N-dimercaptoamide, N,N-dimercaptoacetamide, N-decylpyrrolidone, sterol , ethanol, n-propanol, isopropanol, water, ethylene glycol dioxime ether, tetrahydrofuran, diisopropyl ether, ethyl acetate, acetone, cyclohexanone, trichlorodecane, tetrachlorodecane, disulfoxide , citric acid, acetic acid, or a suitable mixture thereof.
、 根据权利要求 7所述的方法,所述酸溶液是氯化氢的 N,N-二曱 基曱酰胺溶液、 氯化氢的 N,N-二曱基乙酰胺溶液、 氯化氢的曱 醇溶液、 氯化氢的乙醇溶液、 氯化氢的正丙醇溶液、 盐酸、 氯 化氢的乙酸乙酯溶液、 氯化氢的四氢呋喃溶液、 氢溴酸、 氢碘 酸、 磷酸及磷酸水溶液、 硫酸水溶液、 硫酸曱醇溶液、 硫酸乙 醇溶液、 多聚磷酸、 曱酸、 乙酸、 三氟乙酸、 乙酸水溶液和乙 酸四氢呋喃溶液, 优选氯化氢的 N,N-二曱基曱酰胺溶液、 氯化 氢的四氢呋喃溶液、 氯化氢的曱醇溶液、 氯化氢的乙醇溶液、 盐酸水溶液、 氢溴酸水溶液、 硫酸水溶液、 硫酸曱醇溶液和硫 酸乙醇溶液。The method according to claim 7, wherein the acid solution is a N,N-dimercaptoamide solution of hydrogen chloride, a N,N-dimercaptoacetamide solution of hydrogen chloride, a sterol solution of hydrogen chloride, and an ethanol of hydrogen chloride. Solution, n-propanol solution of hydrogen chloride, hydrochloric acid, ethyl acetate solution of hydrogen chloride, tetrahydrofuran solution of hydrogen chloride, hydrobromic acid, hydroiodic acid, phosphoric acid and phosphoric acid aqueous solution, aqueous sulfuric acid solution, decyl alcohol solution, ethanolic acid solution, polypolymer Phosphoric acid, citric acid, acetic acid, trifluoroacetic acid, aqueous acetic acid and tetrahydrofuran solution, preferably N,N-dimercaptoamide solution of hydrogen chloride, tetrahydrofuran solution of hydrogen chloride, sterol solution of hydrogen chloride, ethanol solution of hydrogen chloride, aqueous hydrochloric acid solution , aqueous hydrobromic acid solution, aqueous sulfuric acid solution, sterol sulfate solution and sulfuric acid ethanol solution.
0、 根据权利要求 7所述的方法, 其中所述固体酸系统包含作为分 散相或固定相的固载在活性碳、 氧化硅、 氧化铝或硅藻土载体 上的硫酸、 磷酸、 硼酸或杂多酸、 或酸性离子交换树脂, 和作 为连续相或流动相的适宜溶剂组成, 其中所述溶剂选自下列物 质: N,N-二曱基曱酰胺、 N,N-二曱基乙酰胺、 N-曱基吡咯烷酮、 曱醇、 乙醇、 正丙醇、 异丙醇、 水、 乙二醇二曱醚、 四氢呋喃、 异丙醚、 乙酸乙酯、 丙酮、 环己酮、 三氯曱烷、 四氯曱烷、 二 曱亚砜、 曱酸、 乙酸, 或它们适宜的混合物。 0. The method according to claim 7, wherein the solid acid system comprises sulfuric acid, phosphoric acid, boric acid or miscellaneous supported on a carrier of activated carbon, silica, alumina or diatomaceous earth as a dispersed phase or a stationary phase. a polyacid, or an acidic ion exchange resin, and a suitable solvent as a continuous phase or a mobile phase, wherein the solvent is selected from the group consisting of Qualitative: N,N-dimercaptoamide, N,N-dimercaptoacetamide, N-decylpyrrolidone, decyl alcohol, ethanol, n-propanol, isopropanol, water, ethylene glycol diterpene ether, Tetrahydrofuran, diisopropyl ether, ethyl acetate, acetone, cyclohexanone, trichlorodecane, tetrachlorodecane, disulfoxide, citric acid, acetic acid, or a suitable mixture thereof.
、 根据权利要求 1 - 4任何一项所述的方法, 其中式 (IV-0)所示 化合物的用量相对于 1 摩尔的式 (III-0)所示化合物或其盐是 1~10摩尔, 优选 1~3摩尔。 The method according to any one of claims 1 to 4, wherein the compound of the formula (IV-0) is used in an amount of from 1 to 10 mol based on 1 mol of the compound of the formula (III-0) or a salt thereof. It is preferably 1 to 3 moles.
、 根据权利要求 1的方法,还包括将所得的式 (11-0)所示化合物或 其盐与式(V-0 )所示化合物反应,
Figure imgf000019_0001
The method according to claim 1, further comprising reacting the obtained compound of the formula (11-0) or a salt thereof with a compound represented by the formula (V-0),
Figure imgf000019_0001
其中, X代表羟基、 氟、 氯、 溴或碘;  Wherein X represents hydroxy, fluoro, chloro, bromo or iodo;
R6代表如下式所示的取代基 R 6 represents a substituent represented by the following formula
Figure imgf000019_0002
Figure imgf000019_0002
其中 R7、 、 和 。各自独立地代表氢、 氟、 氯、 溴、 碘、 硝基、 ( ^烷基、 d.4烷 L &、 C 4烷氧羰基、 二(d.4 )^基) J^、 C"烷硫基、 C"烷基亚磺酰基、 C"烷基磺酰基、 或具 有 1-9个选自氟、 氯、 溴、 碘的卤素原子的卤代 d_4烷基、 卤 代 d_4烷! L &、 卤代 d_4烷硫基、 卤代 d_4烷基亚磺酰基或卤 代 d_4烷基磺酰基; Y代表氧、 硫、 亚磺酰基或磺酰基; Ar代 表未取代的或由一个、两个或多个取代基取代的苯基、(X -萘基、 P -萘基、 四氢萘基或茚基, 其中的取 选自氟、 氯、 溴、碘、 ( ^烷基、 d.8烷氧基、 d.8烷氧 ^&、 二(( ^烷基) &、 d_8烷硫基、 d_8烷基亚磺酰基、 d_8烷基磺酰基、 具有 1-9个 选自氟、 氯、 溴、碘的相同或不相同卤素原子的卤代 烷基、 卤代 烷! L &、 卤代 d_4烷硫基、 卤代 d_4烷基亚磺酰基或 卤代 d_4烷基磺酰基、具有 3-7个^^子的环烷基、或苯基 Ci.4 烷基、 苯氧基 烷基或苯 L &, Where R 7 , , and . Each independently represents hydrogen, fluorine, chlorine, bromine, iodine, nitro, (^alkyl, d. 4 alkane L &, C 4 alkoxycarbonyl, bis(d. 4 )^) J^, C" alkane thio, C "alkylsulfinyl, C" alkylsulfonyl group, or an 1-9 substituents selected from fluoro, halo is a halogen atom chlorine, bromine, iodine d_ 4 alkyl, halo d_ 4 alkyl! L &, halogenated d 4 alkylthio, halogenated d 4 alkylsulfinyl or halogenated d 4 alkylsulfonyl; Y represents oxygen, sulfur, sulfinyl or sulfonyl; Ar represents unsubstituted or a phenyl group substituted with one, two or more substituents, (X-naphthyl, P-naphthyl, tetrahydronaphthyl or anthracenyl, the one selected from the group consisting of fluorine, chlorine, bromine, iodine, (^alkyl, d. 8 alkoxy, d. 8 alkoxy^&, bis((alkyl) &, d- 8 alkylthio, d- 8 alkylsulfinyl, d- 8 alkylsulfonyl, Haloalkyl, haloalkane having 1-9 identical or different halogen atoms selected from fluorine, chlorine, bromine, iodine! L &, halogenated d 4 alkylthio, halogenated d 4 alkylsulfinyl or halogenated d_ 4 alkylsulfonyl group having 3-7 ^^ sub cycloalkyl, Ci.4 alkyl, or phenyl, phenoxy or phenyl group L &,
制得式(1-0 )所示的化合物,
Figure imgf000020_0001
Producing a compound represented by the formula (1-0),
Figure imgf000020_0001
其中 Re如上定义; R,和 R"的定义同权利要求 1。  Wherein Re is as defined above; R, and R" are as defined in claim 1.
、 根据权利要求 12的方法, 其中在式(V-0 )和式(1-0 ) 中, Re 代表如下式所示的取代基 The method according to claim 12, wherein in the formula (V-0) and the formula (1-0), Re represents a substituent represented by the following formula
Figure imgf000020_0002
Figure imgf000020_0002
其中, R7、 、 和 。各自独立地代表氢、 氟、 氯、 溴、 碘、 硝基、 曱基、 乙基、 曱氧基、 乙氧基、 曱氧基羰基、 乙氧基羰 基、 二曱基 ^&、 二乙基 ^、 曱硫基、 乙硫基、 曱烷基亚磺 酰基、 乙烷基亚磺酰基、 曱基磺酰基、 乙基磺酰基、或具有 1-5 个选自氟、 氯、 溴、 碘的相同或不相同卤素原子的卤代曱基、 卤代乙基、 卤代曱氧基、 卤代乙氧基、 卤代曱硫基、 卤代乙硫 基、 代曱基亚磺酰基、 代乙基亚磺酰基、 代曱基磺酰基 或卤代乙基磺酰基, 优选地为氢、 曱基、 乙基、 曱氧基、 乙氧 基; X代表氧、硫、 亚磺酰基或磺酰基, 优选地为氧; Ar代表 未取代的或由一个、 两个或多个取 取代的苯基、 a -萘基、 P -萘基、四氢萘基或茚基,其中的取 选自氟、氯、溴、碘、Among them, R 7 , , and . Each independently represents hydrogen, fluorine, chlorine, bromine, iodine, nitro, decyl, ethyl, decyloxy, ethoxy, decyloxycarbonyl, ethoxycarbonyl, dimercapto, and diethyl ^, thiol, ethylthio, decylsulfinyl, ethanesulfinyl, decylsulfonyl, ethylsulfonyl, or having 1-5 selected from the group consisting of fluorine, chlorine, bromine, and iodine Halogenated fluorenyl, haloethyl, halodecyloxy, haloethoxy, halothiol, haloethylthio, decylsulfinyl, substituted B, same or different halogen atom a sulfinyl group, a decylsulfonyl group or a haloethylsulfonyl group, preferably hydrogen, decyl, ethyl, decyloxy, ethoxy X represents oxygen, sulfur, sulfinyl or sulfonyl, preferably oxygen; Ar represents unsubstituted or substituted by one, two or more phenyl, a-naphthyl, P-naphthyl, a tetrahydronaphthyl or an anthracenyl group selected from the group consisting of fluorine, chlorine, bromine, and iodine
( ^烷基、 d.6烷氧基、 d.6烷氧 ^&、 二(d.6烷基) &、 d_3烷硫基、 d_3烷基亚磺酰基、 d_3烷基磺酰基、 具有 1-7个 选自氟、 氯、 溴、 碘的相同或不同卤素原子的卤代 烷基、 卤代 d_3烷硫基、 卤代 d_3烷基亚磺酰基或卤代 d_3烷基磺酰 基、具有 3-7个碳原子的环烷基、或苯基 d_3烷基、苯氧基 C1-3 烷基或苯氧基, 优选地为苯基、 2-曱基苯基、 4-曱基苯基、 2,6- 二曱基苯基、 2,4-二曱基苯基、 2,4,6-三曱基苯基、 (X -萘基、 β -萘基、 四氢萘基或茚基。 (^ Alkyl, d. 6 alkoxy, d. 6 ^ & alkoxycarbonyl, di (d. 6 alkyl) &, d_ 3 alkylthio, d_ 3 alkylsulfinyl, d_ 3 alkylsulfonyl group a haloalkyl group having 1 to 7 identical or different halogen atoms selected from the group consisting of fluorine, chlorine, bromine and iodine, a halogenated d 3 alkylthio group, a halogenated d 3 alkylsulfinyl group or a halogenated d 3 alkylsulfonate An acyl group, a cycloalkyl group having 3 to 7 carbon atoms, or a phenyl d- 3- alkyl group, a phenoxy C 1-3 alkyl group or a phenoxy group, preferably a phenyl group, a 2-decylphenyl group, 4 -nonylphenyl, 2,6-dianonylphenyl, 2,4-didecylphenyl, 2,4,6-tridecylphenyl, (X-naphthyl, β-naphthyl, tetra Hydronaphthyl or anthracenyl.
、 根据权利要求 12所述的方法,其中式(11-0)所示化合物或其盐 是式(II)所示的化合物或其盐, 式( V-0 )所示化合物是式( V ) 或(VI )所示的化合物, 并且 (1-0)所示化合物或其盐是式(I ) 所示化合物或其盐。 The method according to claim 12, wherein the compound of the formula (11-0) or a salt thereof is a compound represented by the formula (II) or a salt thereof, and the compound represented by the formula (V-0) is a formula (V) Or a compound represented by (VI), and the compound represented by (1-0) or a salt thereof is a compound of the formula (I) or a salt thereof.
Figure imgf000021_0001
Figure imgf000021_0001
PCT/CN2008/070218 2007-01-30 2008-01-30 Preparation method of thioureas or salts thereof WO2008092410A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN200710078155.7 2007-01-30
CN 200710078155 CN101235018B (en) 2007-01-30 2007-01-30 Modified method for preparing (1,4,5,6-tetrahydro-2-pyrimidyl)thiourea or salts thereof

Publications (1)

Publication Number Publication Date
WO2008092410A1 true WO2008092410A1 (en) 2008-08-07

Family

ID=39673679

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2008/070218 WO2008092410A1 (en) 2007-01-30 2008-01-30 Preparation method of thioureas or salts thereof

Country Status (2)

Country Link
CN (1) CN101235018B (en)
WO (1) WO2008092410A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101762651B (en) * 2008-12-12 2013-06-12 重庆医药工业研究院有限责任公司 Method for measuring abafungin content and impurity by using high performance liquid chromatography
CN101769903B (en) * 2008-12-29 2014-03-05 北京德众万全药物技术开发有限公司 Method utilizing HPLC (high performance liquid chromatography) to measure substances relevant to abafungin

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4581453A (en) * 1982-05-28 1986-04-08 Bayer Aktiengesellschaft Guanidinothiazole derivatives containing alkylene bridges, and their use for influencing lipid metabolism
US4956370A (en) * 1988-10-24 1990-09-11 Bayer Aktiengesellschaft Antimycotically active substituted 2-aminothiazoles
US5104879A (en) * 1988-10-24 1992-04-14 Bayer Aktiengesellschaft Antimycotically active substituted 2-aminothiazoles

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4581453A (en) * 1982-05-28 1986-04-08 Bayer Aktiengesellschaft Guanidinothiazole derivatives containing alkylene bridges, and their use for influencing lipid metabolism
US4956370A (en) * 1988-10-24 1990-09-11 Bayer Aktiengesellschaft Antimycotically active substituted 2-aminothiazoles
US5104879A (en) * 1988-10-24 1992-04-14 Bayer Aktiengesellschaft Antimycotically active substituted 2-aminothiazoles

Also Published As

Publication number Publication date
CN101235018B (en) 2011-05-04
CN101235018A (en) 2008-08-06

Similar Documents

Publication Publication Date Title
US8884033B2 (en) Process for preparing aminobenzoylbenzofuran derivatives
JP4669564B2 (en) Novel process for the preparation of 2-imino-thiazolidin-4-one derivatives
JP5260636B2 (en) Process for producing pyrazole
TW201509415A (en) Process for the preparation of 4-{4-[({[4-chloro-3-(trifluoromethyl)-phenyl]amino}carbonyl)amino]-3-fluorophenoxy}-N-methylpyridine-2-carboxamide, its salts and monohydrate
JPH0460990B2 (en)
WO2010142653A1 (en) A process for the preparation of febuxostat
KR20190013553A (en) Improved process for preparing aminopyrimidine derivatives
JP5458093B2 (en) Method for synthesizing 3,6-dihydro-1,3,5-triazine derivatives
WO2008092410A1 (en) Preparation method of thioureas or salts thereof
US10858353B2 (en) Intermediates useful for the synthesis of aminopyrimidine derivatives, process for preparing the same, and process for preparing aminopyrimidine derivatives using the same
JP4770826B2 (en) Method for producing 2-oxindole derivatives
EP2118058B1 (en) Method for the preparation of 5-benzyloxy-2-(4-benzyloxphenyl)-3-methyl-1h-indole
CN112390725A (en) Preparation method of amide compound
US9738607B2 (en) Scalable process for the preparation of Sorafenib tosylate ethanol solvate and Sorafenib tosylate form III
KR20010076278A (en) 3-(1-Hydroxy-Pentylidene)-5-Nitro-3H-Benzofuran-2-One, a Process for the Preparation thereof and the Use thereof
AU2010313521B2 (en) Methods of preparing 1-(4-((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone
WO2022177016A1 (en) Method for manufacturing azole derivative
JP4587139B2 (en) A method for producing an aminoalkoxycarbostyril derivative.
JP4144223B2 (en) Method for producing chromone derivative
US20070037854A1 (en) Process for preparing sulfonamide-containing indole compounds
CN110903245A (en) Key intermediate for synthesizing 1-alkyl-2-trifluoromethyl-5-amino-1H-imidazole and preparation method thereof
JP2019210284A (en) Method for manufacturing diarylketone compound
JP2008266199A (en) Method for producing n-(2-amino-1,2-dicyanovinyl)formamidine
KR20100042835A (en) Process for preparing substituted benzamide derivatives
JP2004250340A (en) Method for producing 4-hydrazinotetrahydropyrane compound or its acid salt

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08706595

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 5521/DELNP/2009

Country of ref document: IN

122 Ep: pct application non-entry in european phase

Ref document number: 08706595

Country of ref document: EP

Kind code of ref document: A1